Oxidative stress regulates DTNBPI/Dysbindin-1 Expression and Degradation via a Pest Sequence in it s C-Terminus by YAP MEI YI ALICIA
 Oxidative Stress Regulates DTNBP1/Dysbindin-1 Expression 





YAP MEI YI ALICIA 
 (B.Sc. (Hons), NUS) 
 
 
SUPERVISOR: ASSOCIATE PROFESSOR LO YEW LONG 
CO-SUPERVISOR: ASSOCIATE PROFESSOR ONG WEI YI 
 
A THESIS SUBMITTED FOR THE DEGREE OF 
MASTER OF SCIENCE 
 
DEPARTMENT OF ANATOMY 
YONG LOO LIN SCHOOL OF MEDICINE 














I hereby declare that the thesis is my original work 
and it has been written by me in its entirety. 
I have duly acknowledged all the sources of 
information which have been used in the thesis. 
 
This thesis has also not been submitted for any 







YAP MEI YI ALICIA 








I would like to offer my deepest appreciation to my supervisor, Associate 
Professor Lo Yew Long, Department of Anatomy, National University of 
Singapore, for his utmost support throughout the course of my project; and to my 
co-supervisor Associate Professor Ong Wei Yi, Department of Anatomy, 
National University of Singapore, for his patient guidance and encouragement 
throughout my entire candidature. His patience, constructive criticisms and kind 
understanding have played a major role in the accomplishment of this thesis.  
I would also like to extend my utmost gratitude to my mentors; Jinatta 
Jittiwat, Kazuhiro Tanaka and Tang Yan for imparting invaluable techniques 
that are essential in this study and without them this thesis would have remained 
a dream. To my fellow seniors; Chia Wan Jie, Kim Ji Hyun, Ma May Thu, Ng 
Pei Ern Mary, and Poh Kay Wee, I am deeply grateful for your timely advice 
and never ending encouragement that assisted me in overcoming obstacles 
faced. My thanks and appreciation also goes to Ms Ang Lye Geck, Carolyne 
and Mdm Dilijit Kour D/O Bachan Singh for their secretarial assistance. To my 
peers; Chew Wee Siong, Ee Sze Min and Loke Sau Yeen, and juniors; Chan 
Vee Nee, Shalini D/O Suku Maran, Tan Siew Hon Charlene, and Tan Wee 
Shan Joey, a big thank you for standing by me during the completion of this 
thesis. 
Last but not least, to my dad and mom; Winson and Cathryn, and sister; 
Gloria, thank you for always believing that I could achieve greater heights and to 
my beloved; Jonathan, for his endless support and understanding. 




TABLE OF CONTENTS 
CONTENTS PAGE 
  
Declaration Page I 
Acknowledgements II 
Table of Contents III 
Summary VI 
List of Figures VII 
Abbreviations IX 
  
CHAPTER 1 – INTRODUCTION 1 
1.1 Schizophrenia 2 
1.2 Role of genetics in schizophrenia 3 
 1.2.1 Role of dysbindin-1 in schizophrenia 5 
  1.2.1.1 Dysbindin and its protein family 5 
  1.2.1.2 Dysbindin and its functions 6 
1.3 Role of environment in schizophrenia 14 
1.4 Role of oxidative stress in schizophrenia 16 
 1.4.1 Kainic acid-mediated excitotoxicity 18 
1.5 PEST sequence as a protein degradation signal peptide 20 
          
CHAPTER 2 – HYPOTHESIS AND AIMS  21 
  
CHAPTER 3 – CHANGES IN DYSBINDIN-1 CORE PROMOTER 
ACTIVITY AFTER OXIDATIVE STRESS  
23 
3.1 Introduction  24 
3.2 Materials and Methods 26 
 3.2.1 Cells and Constructs 26 
 3.2.2 Dual-Luciferase® Reporter Assay 28 
 3.2.3 Effect of oxidative stress on dysbindin-1A core promoter 29 





 3.2.4 Effect of WP631 on dysbindin-1A core promoter activity 29 
3.3 Results 30 
 3.3.1 Effect of oxidative stress on dysbindin-1A core promoter 
activity 
30 
3.4 Discussion 33 
          
CHAPTER 4 – ROLE OF OXIDATIVE STRESS AND PEST 
SEQUENCE ON DYSBINDIN-1 EXPRESSION IN VITRO 
36 
4.1 Introduction  37 
4.2 Materials and Methods 40 
 4.2.1 Cells and Constructs 40 
 4.2.2 Effect of oxidative stress on dysbindin-1A expression 42 
 4.2.3 Effect of the proteasome inhibitor on dysbindin-1A 
expression 
42 
 4.2.4 Effect of the PEST sequence of dysbindin-1A on protein 
expression after oxidative stress 
43 
 4.2.5 Western blot analyses 43 
4.3 Results 46 
 4.3.1 Effect of oxidative stress and oxygen free radicals on 
dysbindin-1A expression 
46 
 4.3.2 Effect of proteasome inhibitor and the PEST sequence on 
dysbindin-1A expression 
48 
 4.3.3 Effect of the PEST sequence of dysbindin-1A on protein 
expression after oxidative stress 
49 
4.4 Discussion 52 
          
CHAPTER 5 – ROLE OF KAINATE EXCITOTOXICITY ON 
DYSBINDIN-1 EXPRESSION IN VIVO 
56 
5.1 Introduction 57 
5.2 Materials and Methods 60 




 5.2.1 Kainate injections 60 
 5.2.2 Immunohistochemistry 60 
 5.2.3 Real time RT-PCR analyses 62 
 5.2.4 Western blot analyses 63 
5.3 Results 64 
 5.3.1 Effect of oxidative stress on dysbindin-1 localization in the 
hippocampal formation 
64 
 5.3.2 Effect of oxidative stress on dysbindin-1 mRNA and protein 
expression in vivo 
68 
5.4 Discussion 71 
          
CHAPTER 6 - CONCLUSION 74 
          








Variation in the gene encoding dysbindin-1, dystrobrevin binding protein 1 
(DTNBP1), has been associated with schizophrenia. Dysbindin-1 protein levels 
are reduced in several brain areas including the hippocampus in affected 
individuals. However, this may not be related to decrease DTNBP1 mRNA 
expression. Increasing number of studies has shown that oxidative stress 
resulting from the production of reactive oxygen species and nitrogen reactive 
species is an etiological factor in schizophrenia. Therefore, we tested whether 
oxidative stress modulates DTNBP1 mRNA expression. Using DTNBP1 
transcription reporter, we found that oxidative stress induced DTNBP1 mRNA 
expression and this induction was abolished by a putative Sp1 inhibitor, WP631. 
Intriguingly, oxidative stress and free radicals induced degradation of the 
dysbindin-1 protein, as confirmed by treatment with the free radical scavenger, 
PBN, the proteasome inhibitor, MG132, and by monitoring protein turnover of a 
truncated dysbindin-1 protein, devoid of PEST domain. Excitotoxic injury and 
oxidative stress, triggered by intracerebroventricular kainate injections, resulted 
in increased number of dysbindin-1 expressing neurons in the dentate gyrus and 
CA1, but decreased number of neurons in CA3 of the hippocampus, at 1 day 
post-injection. Together, these findings suggest that, while oxidative stress 
increases DTNBP1 transcription, it strongly promotes dysbindin-1 protein 
degradation, leading to the reported loss of dysbindin-1 protein in the brain of 
schizophrenia patients.  
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1.1 Schizophrenia  
Schizophrenia is a severe and complex mental disorder (Mueser and 
McGurk, 2004; Lindenmayer et al., 2007) with an estimated lifetime prevalence of 
0.72% (McGrath et al., 2008). That means about 50 million people alive today 
are or will be affected with this disorder in their lifetime. Symptoms of 
schizophrenia are evident usually in late adolescence and early adulthood, with 
an incidence equal among sexes, though reports have shown that females tend 
to display its symptoms earlier than males, and with a less severe form of 
schizophrenia (Angermeyer et al., 1990). Despite males and females having 
equal chances of suffering from schizophrenia, its occurrence differs across the 
world, within each country and even one’s household (Kirkbride et al., 2007).  
This affliction is expressed in three core features: (1) positive symptoms 
such as disorganized speech, hallucinations, and delusions (Andreasen et al., 
1995; Lindenmayer et al., 2007), (2) negative symptoms including absence of 
motivation, inability to experience pleasure, and poverty of speech (Andreasen et 
al., 1995; Lindenmayer et al., 2007; Mäkinen et al., 2008), and (3) cognitive 
deficits such as impaired working memory, reduced executive function, and 
conceptual disorganization (Green et al., 2000; Sharma and Antonova, 2003; 
Lesh et al., 2011). In view of these symptoms, schizophrenia patients could 
potentially face difficulties in their daily lives which include, work, school, 
parenting, and dealings with interpersonal relationships (Mueser and McGurk, 
2004). Current drug treatments often ameliorate the positive symptoms, but have 







2012) or cognitive deficits (Fumagalli et al., 2009; Hill et al., 2010; Tcheremissine 
et al., 2012), both of which are more debilitating than the positive features of the 
disorder (Milev et al., 2005; Kurtz, 2006; Tabares-Seisdedos et al., 2008). None 
of the attempts to develop effective treatments for these features of 
schizophrenia over the last decade has succeeded (Hill et al., 2010; Miyamoto et 
al., 2012). Considering the detrimental effects of schizophrenia and a slow 
progress in effective treatments, it is pertinent to further investigate factors that 
could contribute to a lower schizophrenia-susceptibility rate possibly through in 
vivo and in vitro studies to aid the understanding of its etiology and pathogenesis 
of schizophrenia.  
 
1.2 Role of genetics in schizophrenia 
Taking into account the severity of schizophrenia in the human population, 
progressive studies are being carried out to search for the exact cause(s) of 
schizophrenia. Evidence has shown that genetic and environmental factors may 
add to the risk for the onset of schizophrenia (Tsuang, 2000; Sullivan, 2005; van 
Os et al., 2008). Studies have highlighted that the former could have a larger 
impact than the latter on the susceptibility of an individual to schizophrenia 
(Kendler et al., 1994). Schizophrenia is highly heritable and evolves from a 
particular group of genes, which determines an individual’s genetic vulnerability. 
It has been shown that individuals who have a first degree relative or a 
monozygotic twin with the disease run the greatest risk for developing 







Picchioni et al. (2007) also suggest that the onset of schizophrenia could involve 
many genes, each contributing to a small effect. The known and putative 
candidate genes of schizophrenia include dysbindin-1 (DTNBP1) (Blake et al., 
1999), catechol-O-methyltransferase (COMT) (Shifman et al., 2002), disrupted-
in-schizophrenia (DISC) (Blackwood et al., 2001), erbB-4 (a receptor tyrosine-
protein kinase) (Sastry and Sita Ratna, 2004), neuregulin-1 (NRG1) (Stefansson 
et al., 2002), and proline dehydrogenase (PRODH) (Li et al., 2004b). However, 
similar to many other complex diseases, genes that predispose to schizophrenia 
are elusive and are non-exhaustive.  
Although there seems to be an increase in the number of possible 
schizophrenia susceptibility genes, DTNBP1 remains to be the more widely 
accepted candidate gene of schizophrenia (Allen et al., 2008; Sun et al., 2008). 
This is mainly due to its discovery as the first schizophrenia susceptibility gene 
(Straub et al., 2002; Williams et al., 2005), and together with many converging 
evidences supporting its potential role in psychosis and cognition (Barch, 2005; 














1.2.1 Role of dysbindin-1 in schizophrenia  
1.2.1.1 Dysbindin and its protein family 
The dysbindin family is made up of 3 different members, dysbindin-1, 
dysbindin-2, and dysbindin-3, and are found to be expressed in many species but 
are more commonly studied in humans (Talbot et al., 2009). There are 8 human 
dysbindin transcripts (i.e. dysbindin-1A, -1B, -1C, -2A, -2B, -2C, -3A, and -3B) as 
reported in the National Center for Biotechnology Information (NCBI) database. 
Dysbindin-2A, a 261 amino acid protein, is one of the three dysbindin-2 isoforms. 
This full length isoform of dysbindin-2 is the only dysbindin isoform known to 
possess a signal peptide and is postulated to be a precursor of a secretory 
protein (Brunig et al., 2002). Dysbindin-2B is similar to its full length isoform, 
except for its truncated N-terminus region (NTR). This isoform was discovered to 
be an apoptosis response gene (ARG) that was stimulated upon the inactivation 
of a stem cell growth factor (SCF) (Haenggi and Fritschy, 2006). Since a 
reduction or inhibition of programmed cell death has resulted in abnormal 
neuronal development (Rapaport et al., 1991), dysbindin-2B, an ARG, could be 
involved in the normal development of the nervous system. Dysbindin-2C is 
relatively similar to its 2B isoform, with the former having a shorter C-terminus 
region (CTR). Its exact function has yet to be elucidated but studies have shown 
that it is a protein secreted independent of the endoplasmic reticulum (ER) and 
Golgi complex (Kumagai et al., 2001). Dysbindin-3A is a 176 amino acid protein, 
one of the two isoforms identified in dysbindin-3. Till date, no other dysbindin-3A 







amino acid protein shorter than its 3A isoform (Talbot et al., 2009). Similar to 
dysbindin-2C, both dysbindin-3A and -3B are found to be proteins secreted in a 
non-classical manner, independent of the ER and Golgi complex (Talbot et al., 
2009). The main structural difference that distinguishes dysbindin-1 from the rest 
of its members is the presence of the coiled coil domain (CCD) which will be 
described later in this section. Of greater interest, dysbindin-1 unlike its other 
members has shown to be significantly associated with the pathogenesis of 
schizophrenia. Hence, dysbindin-1 will be the focus of this thesis. 
 
1.2.1.2 Dysbindin-1 and its functions 
 
Figure 1.2.1.2 Schematic diagram of dysbindin-1 isoforms in human. Dysbindin-1 isoforms 
are characterized by 3 main regions: 1) C-terminus region (CTR), 2) Coiled coil domain (CCD), 
and 3) N-terminus region (NTR). Dysbindin-1A is the full length dysbindin isoform, while 
dysbindin-1B and dysbindin-1C are exactly like its full length isoform except for a truncated CTR 
which lacks its PEST domain (blue region), or the NTR, respectively [Adapted from (Talbot et al., 
2009)].  
 
Dysbindin-1 is first discovered as a protein binding partner of dystrobrevin, 
a dystrophin-related protein (Benson et al., 2001). Studies have found mutations 







muscular dystrophy (DMD and BMD, respectively) (Blake et al., 1999). A loss 
and reduced level of dystrophin were reported in patients with DMD and BMD, 
respectively (Burdick et al., 2006). Dystrophin is a major component of the 
dystrophin glycoprotein complex (DGC), which is essential in the maintenance of 
muscle membrane integrity and modulation of extracellular signals to the 
cytoskeleton (Nian et al., 2007; Luciano et al., 2009). DGCs found in the muscle 
fibers play an integral role in providing structural support and relaying important 
signals, while DGCs present in the brain may be involved in neurotransmission 
between GABAnergic (Brunig et al., 2002) and glutamatergic neurons (Haenggi 
and Fritschy, 2006). Moreover, in a dystrophin-null (mdx) mouse model, long-
term memory and learning abilities were impaired (Vaillend et al., 2004). 
Therefore, further studies on the interactions of brain DCGs with their component 
proteins such as dystrobrevins could shed light and probably account for the 
learning deficit observed in 18-63% of DMD and 3-25% of BMD patients 
(Rapaport et al., 1991; Kumagai et al., 2001; Talbot et al., 2009). Dystrobrevin is 
one of the major interacting protein partners of DGC and there are two main 
dystrobrevins, the α-isoform which is commonly found in muscles, and the β-
isoform which is present in the brain. Since β-dystrobrevins are expressed in 
nerve cells, unlike α-dystrobrevins which are usually found in muscle cells, 
studies on the potential binding partners of β-dystrobrevin could explain its 
association to cognitive deficit observed in patients with this disorder. 
In 1999, dysbindin-1 was first discovered as a novel β-dystrobrevin 







(Blake et al., 1999). Concurrently, Straub et al. (2002) have identified many 
single nucleotide polymorphisms (SNPs) and risk haplotypes in different regions 
along DTNBP1 that were significantly correlated to schizophrenia. Interest on 
DTNBP1 grew as it was found to be the first schizophrenia-susceptibility gene via 
positional cloning (Straub et al., 2002). Genome-wide association studies and 
bioinformatics analysis have also concluded DTNBP1 as the most promising 
schizophrenia candidate gene (Allen et al., 2008; Sun et al., 2008). 
Schizophrenia is highly heritable (Owen et al., 2002; Gejman et al., 2010), and 
studies on its genetic risk factors can provide important clues to its causes and 
cellular abnormalities. Among the many proposed genetic risk factors in 
schizophrenia (Sun et al., 2008; Gejman et al., 2010) are SNPs or multi-SNP 
haplotypes of the dysbindin-1 gene, DTNBP1. While association of these variants 
with schizophrenia have not met the high level of significance (p < 10-8) required 
in large-scale, genome-wide association studies, they have been substantiated in 
21 studies on smaller, less heterogeneous populations in Asia, Europe, and the 
U.S. (Talbot et al., 2009; Maher et al., 2010; Rethelyi et al., 2010; Voisey et al., 
2010; Fatjo-Vilas et al., 2011). One or more DTNBP1 risk SNPs are associated 
with the severity of negative symptoms (Fanous et al., 2005; DeRosse et al., 
2006; Wirgenes et al., 2009) and cognitive deficits (Burdick et al., 2006; Burdick 
et al., 2007; Donohoe et al., 2007; Zinkstok et al., 2007; Fatjo-Vilas et al., 2011) 
in schizophrenia. These risk SNPs are more evident in a specific group of 
schizophrenia cases distinguished by earlier onset in adulthood and more 







et al., 2009). Moreover, studies have also found that individuals who possess 
SNPs in DTNBP1 associated with schizophrenia but do not display obvious 
symptoms of schizophrenia, exhibit cognitive deficit such as working memory and 
attention impairment (Burdick et al., 2006; Luciano et al., 2009). Genetic variation 
in DTNBP1 is thus associated with schizophrenia in diverse populations and with 
features of the disorder for which we lack adequate treatments. How DTNBP1 
risk variants affect the protein encoded is unclear (Tang et al., 2009; Dwyer et al., 
2010), but it is known that based on postmortem analysis on the brains of 
schizophrenia patients, dysbindin-1 gene and protein expression are reduced 
compared to its matched-paired controls (Weickert et al., 2008; Tang et al., 2009). 
Specifically, levels of dysbindin-1 are reduced in synaptic tissue of the 
dorsolateral prefrontal cortex, auditory association cortices, and hippocampal 
formation (HF) in 67-93% of the schizophrenia cases studied to date (Talbot et 
al., 2004; Tang et al., 2009; Talbot et al., 2011). Given convincing evidence 
showing strong correlation between dysbindin-1 and schizophrenia, further 
studies and analysis on the factors that affect dysbindin-1 expression could 
potentially provide important clues to the pathogenesis and pathophysiology of 
schizophrenia. 
The DTNBP1 gene which translates into the dysbindin-1 protein is found 
at the chromosome locus 6p22.3 in humans and 17 in rats. It is relatively 
abundant in the body, including the brain (Talbot et al., 2004). There are three 
major transcripts namely dysbindin-1A, -1B, -1C (Figure 1.2.1.2). Dysbindin-1A is 







humans and 352 amino acid protein expressed in rats. Dysbindin-1B is similar to 
its full length isoform except for a truncated CTR and is a 303 amino acid protein 
found in humans but not expressed in rats. Dysbindin-1C on the other hand is an 
isoform that lacks a NTR, and is a 270 amino acid protein. It is detected in 
humans but its protein length in rats could not be determined as there is a lack of 
information on this dysbindin paralog (Talbot et al., 2009). Numerous serine and 
threonine kinases sites such as protein kinase B (PKB/Akt) and cyclin-dependent 
kinase 1 (Cdk1) are found in the NTR of dysbindin-1A and -1B (Talbot et al., 
2009). Though its exact function has yet to be elucidated, phosphorylation of 
these sites in the NTR could affect protein-protein binding in the CCD (Talbot et 
al., 2009). The CCD is a region made up of many seven-residue repeats with 
each repeat consisting of alternate hydrophilic and hydrophobic residues, forming 
alpha helices which are able to bind and interact with other proteins with CCD 
(Lupas, 1996; Lupas and Gruber, 2005). It is thus hypothesized that dysbindin-1 
is likely to form interactions with its binding partners at its CCD and thus eliciting 
its functions (Talbot et al., 2009). Of greater interest, the PEST domain (i.e. blue 
region in Figure 1.2.1.2) present in the CTR is a hydrophilic motif that acts as a 
target for degradation upon phosphorylation (Rechsteiner and Rogers, 1996; 
Singh et al., 2006) (please refer to Section 1.5 for more details on the PEST 
domain). 
Dysbindin-1 is widely expressed in the brain, specifically in the axon fibers 
of the corpus callosum, specific group of axon terminals such as the mossy-fiber 







neocortex and substantia nigra (Benson et al., 2001). The key and potential 
functions of dysbindin-1 are believed to be mediated by the different binding 
partners it is associated with. Ring finger protein 151 (RNF151), a known binding 
partner of dysbindin-1, is found to be located in the spermatids and is postulated 
to be involved in spermatogenesis (Nian et al., 2007). Interaction between 
dysbindin-1 and RNF151 is found to induce the formation of acrosome (Nian et 
al., 2007), which is an organelle found at the tip of sperm containing digestive 
enzymes, allowing the fusion between a sperm and ovum (Green, 1978). The 
presence of putative binding factors of dysbindin-1 (e.g. transcription factor IIIB, 
isoform 3 and cyclin A2), transcription factor binding sites (i.e. Sp1 and NF-1) 
found in the promoter region of dysbindin-1, and levels of DTNBP1 gene and 
protein peaking during cell proliferation in prenatal events suggest its vital role in 
cell development (Talbot et al., 2009). Besides its role in cell development, the 
presence of Sp1 (specificity protein 1) transcription factor binding sites in 
dysbindin-1 promoter also suggests a neuroprotective role involved. Cultured 
cerebrocortical neurons which overexpress full length Sp1 were found to be more 
resistant to hydrogen peroxide induced-oxidative stress (Ryu et al., 2003). 
Similarly, despite being deprived from serum, cell viability in cultured 
cerebrocortical neurons which overexpressed dysbindin-1 was increased and 
decreased when the cells were treated with an siRNA inhibitor against dysbindin-
1 (Numakawa et al., 2004). Taken together, dysbindin-1 may be involved in cell 
proliferation and development, and also regulate the population of neurons due 







dysbindin has a significant role in neuronal growth and proliferation, individuals 
who are carriers of the DTNBP1 risk SNPs may be deficient in normal neuronal 
development, and hence may account for the smaller brain volume observed in 
them as compared to non-carriers (Narr et al., 2009). 
The main function of dysbindin-1 may be modulated by biogenesis of 
lysosome-related organelles complex 1 (BLOC-1), which is a multimer consisting 
of different proteins (in addition to dysbindin-1); BLOC-1 subunit-1 (BLOS-1), 
BLOS-2, BLOS-3, cappuccino, muted, pallidin, and snapin (Li et al., 2004c; 
Starcevic and Dell'Angelica, 2004). BLOC-1 is primarily involved in trafficking 
proteins to lysosome-related organelles (LROs) which are essential in its 
maturation and function (Setty et al., 2007). BLOC-1 binds to other protein 
complexes, such as AP-3, an adaptor protein assembly which recognizes 
proteins with a specific signal peptide, and delivers them to their target LROs 
(Bonifacino and Glick, 2004). Evidence has shown that the BLOC-1-AP-3 
complex delivers proteins to LROs present in non-neuronal cells (e.g. 
melanocytes), and neurons (i.e. nerve terminals and axons) (Bonifacino and 
Glick, 2004; Newell-Litwa et al., 2007; Setty et al., 2007). Reduced levels of 
these complexes have reported abnormalities in the formation of synaptic 
vesicles (Newell-Litwa et al., 2009), and the expression of neurotransmitter 
receptors on cell surfaces (Iizuka et al., 2007). These abnormalities could induce 
neurobehavioral hallmarks of schizophrenia seen in mouse and Drosophila 
models which display similar phenotypes observed in schizophrenia patients 







when placed in a new environment, dysbindin-1 deficient (sdy) mice did not 
habituate, unlike matched controls (Hattori et al., 2008; Bhardwaj et al., 2009). 
Habituation is a process of repeated exposure to the same non-threatening 
stimulus that usually results in decreased response, and this adaptive response 
reflects memory of past events (Bhardwaj et al., 2009). The absence of this 
response in sdy mice proposes that the loss of dysbindin-1 could lead to 
cognitive deficits affecting declarative and recognition memory, characteristics 
similar to those observed in schizophrenia patients (Cirillo and Seidman, 2003; 
Pelletier et al., 2005). Taken together, this suggests that dysbindin-1 plays a 
significant role in cognitive functioning and memory (Owen et al., 2004). 
 Of specific interest, dependent on dose and in the absence of Ca2+ influx, 
dysbindin-1 also plays an essential role in intracellular and intercellular signalling, 
modulation of presynaptic retrograde and homeostatic neurotransmission 
(Dickman and Davis, 2009). Moreover, based on electron microscopy, dysbindin-
1 is found to be localized in axon terminals and dendrites of hippocampal 
neurons (Talbot et al., 2009), and sdy mice which have loss of dysbindin-1 
expression showed decrease in the reserve pool of synaptic vesicles (Chen et al., 
2008). In addition, cultured neurons with knockdown of dysbindin-1 showed 
reduced glutamate release (Numakawa et al., 2004). Loss of dysbindin-1 may 
therefore result in decreased communication between glutamatergic neurons that 
may lead to the affliction of schizophrenia expressed by the onset of its 
symptoms (Cherlyn et al., 2010). These reductions in dysbindin-1 may be a 







since such behaviors are observed in sdy mice with loss of DTNBP1 (Talbot, 
2009).  
Many studies on the dorsolateral prefrontal cortex in schizophrenia 
patients have concluded that reduced DTNBP1 transcription is not a cause of the 
reduction in dysbindin-1 (Weickert et al., 2008; Tang et al., 2009; Fung et al., 
2011). In addition, despite many positive large-scale association studies in 
countries such as China (Shi and Liu, 2003), and England (Datta, 2003) yielding 
positive reports, negative studies have also been reported in the U.K. (Sanders 
et al., 2008; Sullivan et al., 2008). These latter reports have found no significant 
association to schizophrenia (Van Den Bogaert et al., 2003; van den Oord et al., 
2003). In a separate study, the frequency of high-risk dysbindin-1 haplotypes (0-
18%) as observed in the schizophrenia population was much lower than the 
frequency of dysbindin-1 reduction (73-93%) as seen in schizophrenia patients 
(Van Den Bogaert et al., 2003; van den Oord et al., 2003). Taken together, these 
discrepancies further suggest that genetics alone may not fully account for the 
susceptibility of schizophrenia and its increased susceptibility is probably due to 
a synergy among genetic and environmental factors. 
 
1.3 Role of environment in schizophrenia  
Since a reduced DTNBP1 transcription could not fully account for the 
reduction in dysbindin-1 protein expression reported in schizophrenia cases, this 
highlights the imperative role of environment in the pathogenesis of 







vulnerability model as proposed by Mueser and McGurk (Mueser and McGurk, 
2004). This model attributes the cause of schizophrenia to psychobiological 
vulnerability that is usually predetermined by genetic and environmental 
conditions early in life and once the vulnerability has been ascertained, the onset 
and the course of the illness are largely dependent on the dynamics of biological 
and psychosocial factors. Biological factors such as medication and substance 
abuse are of great importance as they affect the onset of schizophrenia. Though 
medication may alleviate the severity of symptoms, substance abuse may 
increase the chance of relapses. Additionally, psychosocial factors such as 
stress and social support also play a pertinent role in the course of schizophrenia 
(Mueser and McGurk, 2004). Similarly, epidemiological studies also found that 
environmental risk factors such as early childhood malnourishment (Brown and 
Susser, 2008), drug dependence (Sullivan, 2005), medical conditions (e.g. 
obesity and hypoxia) (Jeste et al., 1996; Mittal et al., 2008) and brain trauma 
(Morgan and Fisher, 2007; Do et al., 2009) are associated with the pathogenesis 
of schizophrenia. Interestingly, environmental stressors as mentioned above (e.g. 
malnourishment, infection, stress and trauma) are known to induce oxidative 
stress (Do et al., 2009) and an increasing number of studies suggest that 
oxidative stress is of great relevance to schizophrenia (Do et al., 2009; 
Bitanihirwe and Woo, 2011; Yao and Keshavan, 2011). Taken together, 
dysbindin-1 reductions might be due to oxidative stress resulting from elevated 







diminished antioxidant activities collectively called the antioxidant defense 
system (Yao and Keshavan, 2011).  
 
1.4 Role of oxidative stress in schizophrenia 
The brain is particularly susceptible to the generation of ROS (i.e. H2O2, 
O2-, OH-, and .OH) and RNS (i.e. .NO and ONOO-) as it is metabolically active 
and contains a considerable amount of polyunsaturated fatty acids (PUFAs) that 
are highly vulnerable to peroxidation and redox-free metals (Mahadik et al., 2001; 
Andersen, 2004; Valko et al., 2007). Moreover, in certain parts of the human 
brain, iron (Fe2+) levels are elevated and ascorbate levels are usually high. When 
the body is under oxidative stress which is inducible by conditions such as stroke 
or aging, the presence of Fe2+ and ascorbate may be potent oxidants to the brain 
membranous layer (Zaleska et al., 1989). However, the presence of free radicals 
is not always detrimental as it is found to be involved in a number of physiological 
functions including intracellular signalling and meiosis (Wood et al., 2009). 
Moreover, the body possess natural defense mechanisms which utilize enzymes 
such as superoxide dismutase (SOD) (which converts superoxide radicals to 
hydrogen peroxide), catalase (CAT) (which converts hydrogen peroxide to water 
and oxygen) and glutathione peroxidise (GPx) (which converts hydrogen 
peroxide into water) to regulate the amount of ROS found in the body. Non-
enzymatic pathways which utilize glutathione, uric acid, and dietary vitamins such 
as Vitamin A, C and E are also present to regulate the amount of ROS generated 







However, excessive production of free radicals for the body’s intrinsic 
natural antioxidant system to cope would eventually lead to oxidative stress. This 
could inevitably lead to oxidative cell injury which is commonly characterized by 
the peroxidation of PUFAs, proteins, and DNA. Based on the findings of many 
(though not all) studies, levels or indices of oxidative stress are increased, while 
antioxidant defenses are decreased in the serum and plasma of schizophrenia 
cases (Gysin et al., 2007; Zhang et al., 2010; Ciobica et al., 2011; Li et al., 2011; 
Yao and Keshavan, 2011). The same imbalance of oxidants and antioxidant 
defenses has also been reported in the cerebrospinal fluid and brain tissue (Do 
et al., 2009; Ciobica et al., 2011; Gawryluk et al., 2011; Yao and Keshavan, 
2011). Levels of serum and plasma levels of oxidative stress markers are 
positively correlated with negative symptoms (Medina-Hernandez et al., 2007; 
Pazvantoglu et al., 2009), while levels of antioxidant glutathione (GSH) in the 
prefrontal cortex are inversely correlated with those symptoms (Matsuzawa et al., 
2008). Moreover, GSH in schizophrenia cases is reduced in the prefrontal cortex 
(Do et al., 2009; Gawryluk et al., 2011). Rodents with GSH deficits share a 
number of features with animal models of schizophrenia, including dysbindin-1 
mutant (sdy) mice (Talbot, 2009; Talbot et al., 2012), specifically reduced 
prepulse inhibition, decreased parvalbumin in fast spiking interneurons, NMDA 
receptor hypofunction, and reduced long term potentiation (LTP) (Dean et al., 
2009; Do et al., 2009). Indeed, oxidative dysfunction of parvalbumin interneurons 
during development has been proposed as a causal factor in schizophrenia 







Taken together, besides genetic factors, oxidative stress has shown to 
play an important role in the pathogenesis of schizophrenia. Hence in this thesis, 
the effects of oxidative stress on dysbindin-1 expression were studied in vitro and 
in vivo by treating human neuroblastoma cells with hydrogen peroxide (H2O2), a 
reactive oxygen species, and using kainic acid (KA) in rats, respectively. 
 
1.4.1 Kainic acid-mediated excitotoxicity  
 
Figure 1.4.1. Schematic diagram of KA-mediated neuronal cell death pathway. (1) Binding of 
KA to Ca2+ AMPA/KA receptors leads to Ca2+ influx; (2) activation of Ca2+ - dependent enzymes 







mitochondrion permeability transition pore; (4) release of mitochondrion factors such as 
cytochrome-c and apoptotic-inducing factor (AIF) (5) triggering apoptosome complex formation 
and caspase-3 pathway activation; (6) leading to nuclear condensation and eventually neuronal 
cell death. On the other hand, Ca2+ influx may lead to excessive ROS production, causing ATP 
decrease, mitochondria damage, protein, lipids and DNA oxidation and ultimately neuronal cell 
death [Adapted from (Wang et al., 2005a)].  
 
KA is a glutamate analogue that acts as an agonist for non- N-methyl-D-
aspartic acid (non-NMDA) receptors such as α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor and KA receptors (Bleakman and 
Lodge, 1998). The administration of KA has shown to increase ROS and RNS 
which not only lead to mitochondrion dysfunction but also trigger apoptosis in 
neurons in different parts of the brain (i.e. CA1, CA3 and hilus of the dentate 
gyrus) (Wang et al., 2005a). These events are elicited by an influx of calcium 
(Ca2+) upon the binding of KA to KA receptors (Sun and Chen, 1998) (Figure 
1.4.1). Taken together, KA is an established experimental model in inducing 
seizures and selective neuronal damage in susceptible limbic structures, 
particularly in the CA3 of the hippocampus (Schwob et al., 1980; Ben-Ari, 1985).  
Since KA can induce oxidative stress and neurodegeneration in vivo 
(Wang et al., 2005a), this study aims to use this glutamate analogue to 
investigate the changes in dysbindin-1 mRNA and protein expression in 
response to oxidative stress in rats. The hippocampus would be emphasized, 
since the former has been long established as one of the brain regions 









1.5 PEST sequence as a protein degradation signal peptide  
A structural feature of two major dysbindin-1 isoforms in the brain 
(dysbindin-1A and -1C) suggests why it may be degraded by oxidative stress. 
These isoforms contain a C-terminus PEST (Proline-Glutamate-Serine-Threonine) 
sequence with many predicted phosphorylation sites, including one for casein 
kinase II (Talbot et al., 2009). It seems the larger the number of proline (P), 
glutamate (E), serine (S), and threonine (T) residues, the lower the hydrophobic 
index and, greater probability of the sequence acting as a proteolytic signal. 
Phosphorylation of predicted kinases sites in the PEST sequence may elicit a 
change in conformation which is recognizable by proteasome, causing the rapid 
degradation of its protein (Rechsteiner and Rogers, 1996; Garcia-Alai et al., 
2006). For example, oxidative stress-induced degradation of a protein, nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IκBα) is 
mediated largely by casein kinase II phosphorylation of its C-terminus PEST 
sequence (Schoonbroodt et al., 2000). Interestingly, Locke et al. also found a 
binding site for E3 ubiquitin ligase, tripartite motif-containing protein 32 (TRIM32) 
which may promote its degradation in the C-terminus of dysbindin-1 (Locke et al., 
2009). Therefore, a mutation in this region may minimize or prevent the reduction 
of dysbindin-1 which is characteristic in schizophrenia cases (Talbot et al., 2004; 
Weickert et al., 2008). Together, this suggests in response to oxidative stress, 
the PEST sequence is important in the regulation of dysbindin-1 present in the 
brain. 
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HYPOTHESIS AND AIMS 
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The present study tests the hypothesis that oxidative stress can affect 
levels of dysbindin-1 expression in the brain via its core promoter, or the protein’s 
PEST domain. Cultured SH-SY5Y neuroblastoma cells were used to determine if 
the putative core promoter sequence of the dysbindin-1 gene (DTNBP1) of Liao 
and Chen (Liao and Chen, 2004) is involved in the regulation of dysbindin-1A 
upon oxidative stress. SH-SY5Y human neuroblastoma cells that stably 
overexpress dysbindin-1A or dysbindin-1A without its PEST sequence were also 
used to determine the effects of oxidative stress, the proteasome inhibitor and 
the PEST sequence of dysbindin-1 on protein expression. The effect of the 
potent glutamate analog, kainic acid (KA), on hippocampal dysbindin-1 
expression was also elucidated. KA induces excitotoxicity in hippocampal 
neurons and since many converging evidences have shown that this is 
associated with oxidative stress and lipid peroxidation (Ong et al., 2000; Wang et 
al., 2005b; Sanganahalli et al., 2006), analyses of dysbindin-1 expression after 
KA might provide insights into effects of oxidative stress on dysbindin-1 





















CHANGES IN DYSBINDIN-1 CORE PROMOTER 









3.1  Introduction 
Several studies have found significant correlations between schizophrenia 
and haplotypes of SNPs in specific genes following the discovery of DTNBP1 as 
a schizophrenia-susceptibility gene (Cloninger, 2002; O'Donovan et al., 2003; 
Owen et al., 2004). Though most of the SNPs associated with increased 
schizophrenia risk were mostly found in the introns (Riley and Kendler, 2006; 
Duan et al., 2007), SNPs were also found in the promoter region of DTNBP1. 
Specifically, Pedrosa et al. have identified a putative promoter site on 
chromosome 6p22.3 that encodes dysbindin-1 (Pedrosa et al., 2009). As shown 
in many studies, this finding is crucial as this specific region formerly mentioned 
contains a SNP site associated with schizophrenia (Numakawa et al., 2004; 
Williams et al., 2004). Converging evidences have also shown high levels of lipid 
peroxidation product such as thiobarbituric reactive substances (TBARS) and 
SOD in schizophrenia patients as compared to controls (D'Angelo and Bresolin, 
2006). Abnormal SOD, GPx and CAT levels were also observed in the blood and 
plasma samples from schizophrenia patients (Herken et al., 2001; Zhang et al., 
2006). Taken together, this suggests that the promoter of dysbindin-1 could be 
involved in its regulation under oxidative stress.  
Dysbindin-1 expression has been widely studied in postmortem brains of 
schizophrenia cases (Talbot et al., 2004; Weickert et al., 2004; Weickert et al., 
2008); however, the effects of oxidative stress which have shown an association 
to schizophrenia on dysbindin-1 promoter have not been clearly studied. 
Therefore, to bridge this gap of knowledge, this chapter aims to understand the 
Chapter 3 





activity of dysbindin-1 promoter under oxidative stress. Cultured SH-SY5Y 
neuroblastoma cells were used to determine if the putative core promoter 
sequence of DTNBP1 of Liao and Chen (Liao and Chen, 2004) is involved in the 
regulation of dysbindin-1A upon oxidative stress.  
 The Dual-Luciferase® Reporter Assay System was used in this study to 
elucidate the activity of dysbindin-1 core promoter activity in response to 
oxidative stress induced by H2O2. The luciferase assay is a technique commonly 
used for the understanding of many aspects in cell biology, and is a reliable tool 
commonly used to study specific cloned promoter sequence activity in vitro in cell 
lines (Greer and Szalay, 2002; Massoud et al., 2007; de Almeida et al., 2011). 
Moreover, translated protein in this system is readily available without the need 
to undergo posttranslational modification (Ow et al., 1986; de Wet et al., 1987), 
allowing rapid quantification with minimal confounding variables. This reporter 
system is sensitive and its quantification method has very minimal interference 
from endogenous expression of host cells (Solberg and Krauss, 2013). 
Measurement results have also shown to be reliable, accurate and reproducible 
(McNabb et al., 2005; Solberg and Krauss, 2013). Together, this suggests that 
the dual luciferase reporter assay is a sensitive and accurate system to 
investigate the promoter activity of dysbindin-1.  
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3.2 Materials and Methods 
3.2.1 Cells and Constructs 
 
Figure 3.2.1 Partial genomic sequence of the promoter sequence of dysbindin-1A. 
Underlined sequences show the forward and reverse primers used, while the sequences in bold 
show the putative dysbindin-1A core promoter sequence proposed by Liao and Chen (2004). 
 
A transient cell line was generated to study the effects of oxidative stress 
on dysbindin-1 core promoter activity. A 630-nt promoter fragment with flanking 
XhoI and HindIII sites including the predicted core promoter of dysbindin-1A was 
isolated using a forward primer (5’-
CAGTCTCGAGAGGACTGGGGATGTCACTCA-3’) and reverse primer (5’-
GTACAAGCTTAACCCAGCCTTCTCCAAG-3’) using rat genomic DNA (Clontech, 
CA, USA) as the template (Figure 3.2.1). Sequences underlined in the forward 
and reverse primers are restriction sites (i.e. XhoI and HindIII respectively). 
Reverse transcription conditions were: 95oC for 30 s, 40 cycles of 95oC for 30 s, 
65oC for 30 s and 72oC for 30 s. The amplification process was completed with 
72oC for 2 min. PCR product was resolved in 1% agarose gel at 100 V in 0.5 X 
TAE buffer that contained 0.5 µg/ml of ethidium bromide. 500bp DNA Ladder 
(Promega, CA, USA) was also loaded. After electrophoresis, the gel was 
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observed under UV light, and bands that corresponded to the putative core 
promoter (630bp) were excised and purified using the QIAquick Gel Extraction 
Kit (Qiagen, CA, USA) according to the manufacturer’s protocol. The purified 
DNA and vector were individually digested. 1 µg of DNA or vector, 5 µl of 10X 
Digestion Buffer and 2.5 µl of XhoI (Promega, #R6161) and 2.5 µl of HindIII 
(Promega, #R6041) was pipetted into a PCR tube and was brought to a total 
volume of 50 µl with nuclease-free water. Reaction was carried out in a PCR 
thermocycler and conditions were as follow: 37oC for 1 h and 65oC for 20 min. 
After linearization, both DNA and vector contained sticky ends that were 
generated by XhoI and HindIII. Ligation of the linearized dysbindin-1A promoter 
DNA sequence into the vector pGL4.10 was completed via the LigaFast™ Rapid 
DNA Ligation System (Promega) according to the manufacturer’s instructions. 
10 µl of ligation product was pipetted into 50 µl of chemically competent E. 
coli cells (Subcloning Efficiency™ DH5α™ competent cells, Invitrogen, CA, USA) 
and mixed gently. This mixture was incubated on ice for 30 min, 42oC water bath 
for 20 s and immediately chilled on ice for 2 min. 1 ml of Lysogeny Broth (LB) 
medium (10 g of tryptone, 5 g of yeast extract and 10 g NaCl in 1 L of distilled 
water and autoclaved) was aseptically added into the vial and centrifuged at 225 
rpm, 37oC for 1 h. 200 µl of the purified transformation mix was added to a LB 
agar plate that contained 50 µg/ml of ampicillin and incubated overnight at 37oC. 
Colonies were selected and added to 5 ml of LB medium containing 50 µg/ml of 
ampicillin. The suspension was centrifuged at 225 rpm at 37oC overnight. 
Ampicillin-resistant DNA plasmids were extracted using the QIAprep Spin 
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Miniprep Kit (Qiagen, #27104). SH-SY5Y cells (CRL-2266™, ATCC) were 
cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Gibco, Invitrogen). Samples with a density of 1.0 X 105 
cells/well were seeded into a 24-well plate and incubated at 37oC for 1 day. The 
DNA sequence was verified via reverse transcription polymerase chain reaction 
(RT-PCR) and DNA sequencing before transfection was carried out.  
 
3.2.2 Dual-Luciferase® Reporter Assay 
The Dual-Luciferase® Reporter Assay system was used to study 
dysbindin-1 core promoter activity in response to oxidative stress. In this assay, 
two individual reporter enzymes were expressed simultaneously in a single 
system. One reporter enzyme (i.e. the firefly luciferase) measures the activity of 
the dysbindin-1A core promoter while the other provided an internal control and 
in this study, was shown by the ratio of firefly luciferase (vector containing 
dysbindin-1A core promoter) to renilla luciferase (reporter control). The verified 
DTNBP-1A XhoI/HindIII construct and pGL4.74 expression control vector were 
co-transfected into SH-SY5Y cells using Lipofectamine® LTX with Plus™ 
(Invitrogen) according to the manufacturer’s protocol. To minimize the possibly of 
trans effect between promoter elements, a small amount of control vector (ratio 










3.2.3 Effect of oxidative stress on dysbindin-1A core promoter activity 
SH-SY5Y cells were co-transfected with the verified DTNBP-1A 
XhoI/HindIII construct and pGL4.74 expression control vector as mentioned 
above, and divided into 4 groups: 1) Treatment with vehicle, 2) Treatment with 50 
µM H2O2, 3) Treatment with 200 µM H2O2, 4) Treatment with 500 µM H2O2. Cells 
were treated for 24 h and luciferase luminescence values were determined using 
the Dual-Luciferase® Reporter Assay (Promega) according to the manufacturer's 
instructions. The mean ratio of firefly:renilla luminescence values and standard 
errors were calculated and any possible significant differences were analyzed by 
1 way ANOVA with Tukey’s multiple comparison post-hoc test (n=5 in each 
group). P < 0.05 was considered significant. 
 
3.2.4 Effect of WP631 on dysbindin-1A core promoter activity 
SH-SY5Y cells were co-transfected with the DTNBP-1A XhoI/HindIII 
construct and pGL4.74 expression control vector as mentioned above and 
divided into 4 groups: 1) Treatment with vehicle, 2) Treatment with 500 nM 
WP631, 3) Treatment with 500 µM H2O2, 4) Treatment with 500 µM H2O2 and 
500 nM WP631 dihydrochloride. The experiment was repeated with 1 µM WP631. 
Cells were treated for 24 h and luminescence values were determined. The 
mean ratio of firefly:renilla luminescence values and standard errors were 
calculated and any possible significant differences were analyzed by 1 way 
ANOVA with Tukey’s multiple comparison post-hoc test (n=5 in each group). P < 
0.05 was considered significant. 
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Figure 3.3.1. Fold change in firefly:renilla luciferase activity of SH-SY5Y cells after 24 h. A: 
Firefly luciferase activity of SH-SY5Y cells co-transfected with the predicted core promoter of 
DTNBP-1A XhoI/HindIII construct and pGL4.74 expression control vector and treated with 0 µM, 
50 µM, 200 µM or 500 µM of H2O2. B: Firefly luciferase activity of SH-SY5Y cells co-transfected 
with the predicted core promoter of DTNBP-1A XhoI/HindIII construct and pGL4.74 expression 
control vector and treated with: 1) vehicle control, 2) 500 nM WP631 dihydrochloride, 3) 500 µM 
H2O2, 4) 500 µM H2O2 and 500 nM WP631 dihydrochloride. C: Firefly luciferase activity of SH-
SY5Y cells co-transfected with the predicted core promoter of DTNBP-1A XhoI/HindIII construct 
and pGL4.74 expression control vector and treated with: 1) vehicle control, 2) 1 µM WP631 
dihydrochloride, 3) 500 µM H2O2, 4) 500 µM H2O2 and 1 µM WP631 dihydrochloride. The mean 
+SE are shown. * indicates significant difference (P < 0.05) compared to control. # indicates 
significant difference compared to SH-SY5Y cells treated with WP631. ^ indicates significant 
difference compared to SH-SY5Y cells treated with 500 µM H2O2. 
 
SH-SY5Y cells that were transiently transfected with DTNBP-1A 
XhoI/HindIII construct and pGL4.74 expression control vector, and treated with 
different H2O2 concentrations, showed 1.22-fold, 1.38-fold, 1.47-fold increase in 
the ratios of firefly:renilla luciferase activity after treatment with 50 µM, 200 µM 
and 500 µM H2O2 respectively as compared to vehicle, indicating activation of 
dysbindin-1A core promoter as a result of oxidative stress (Figure 3.3.1A). In 
contrast, firefly and renilla luciferase expressing cells treated with 500 nM or 1 























































luminescence to 1.17-fold and to 0.60-fold respectively, compared to SH-SY5Y 
cells treated with H2O2 only (Figures 3.3.1B and C). The results suggest that 










The present study was carried out to elucidate the effect of oxidative 
stress on dysbindin-1 promoter activity. In vitro studies were first carried out. SH-
SY5Y cells were transiently transfected with the dysbindin-1A core promoter, and 
activity of the dysbindin-1 promoter after H2O2 treatment was analyzed. Increased 
luciferase activity after treatment with H2O2 indicates increased promoter activity, 
and suggests that the core promoter of dysbindin-1 is involved in the 
upregulation of dysbindin-1A expression after oxidative stress. The exact 
mechanism for this effect is unknown, although oxidative stress has been found 
to affect gene expression (Okamoto et al., 2002; Liu et al., 2004; Zhao and Meng, 
2005). Some studies have shown that the activation of the specificity protein 1 
(Sp1) which is a cis-acting regulator of dysbindin-1A may account for an increase 
in dysbindin-1A expression (Ryu et al., 2003; Iwanaga et al., 2006; Lee et al., 
2006).  
Sp1 is found to stimulate the activation of promoter sequences involved in 
the transcription of a variety of genes (Li et al., 2004a) that modulates cell growth 
(Karlseder et al., 1996), embryogenesis (Zhao and Meng, 2005), NMDA subunit 
1 (Okamoto et al., 2002; Liu et al., 2004), and adaptive strategies induced by 
oxidative stress (Ryu et al., 2003; Lee et al., 2006). For example, Sp1 is capable 
of binding to E2F1; a gene promoter and in the presence of different cellular 
conditions, the latter would elicit a wide array of cellular processes such as DNA 
repair, cell growth, and apoptosis. In the face of serum deprivation of embryonic 
fibroblasts that were transfected with dysbindin-1A, E2F1 was found to be 
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ectopically expressed. This resulted in a 10-fold increase in dysbindin-1 mRNA 
expression (Iwanaga et al., 2006). Therefore, the significant increase in 
dysbindin-1A mRNA as observed in this study could be due to the activation of 
Sp1 under oxidative stress. 
The increase in luciferase activity was then abolished by WP631 
dihydrochloride. This is a DNA intercalator which inhibits transcription and could 
act as a direct competitor of the Sp1 transcription factor (Martin et al., 1999; 
Portugal et al., 2001; Gaidarova and Jimenez, 2002; Mansilla and Portugal, 
2008). Studies have showed that WP631 has a higher specificity and potency 
towards Sp1-DNA complexes as compared to other Sp1 inhibitors such as 
daunorubicin (Villamarin et al., 2003), doxorubicin (Mansilla et al., 2007) and 
mitoxantrone (Gaidarova and Jimenez, 2002). WP631 is also able to elicit high 
inhibitory efficiency at nanomolar concentrations in vitro and in vivo (Portugal et 
al., 2001; Gaidarova and Jimenez, 2002; Villamarin et al., 2002). An online 
programme analysis (Prestridge, 1995) of the core dysbindin promoter has 
identified 7 out of 17 transcription factor binding sites were for Sp1. Hence, the 
significant decrease in luciferase activity observed in transfected cells treated 
with WP631 is likely due to Sp1 inhibition. Taken together, results suggest Sp1 
binding sites present in dysbindin-1 core promoter may be involved in the 
upregulation of dysbindin-1 under oxidative stress.  
No doubt this present study highlighted the possible role of Sp1 binding 
site in the upregulation of dysbindin-1 upon oxidative stress, it has its limitations. 
Besides Sp1, another transcription factor, nuclear factor 1 (Gronostajski, 2000; 
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Plachez et al., 2008), which is also unambiguously found in the core promoter of 
dysbindin-1 may regulate dysbindin-1 expression. Moreover, WP631 has been 
reported to affect other transcription function such as smad (Botella et al., 2001; 
Li et al., 2008) and nuclear factor (NF)- κB (Ashikawa et al., 2004), or the 
transactivation of Tat (Kutsch et al., 2004). Hence, present studies carried out 
could only suggest that Sp1 is involved in modulating dysbindin-1 expression 
upon oxidative stress. To validate and propose Sp1 as an activator of dysbindin-
1, further studies such as (1) mutagenesis of Sp1 binding site, (2) Sp1 
knockdown experiment by siRNA, and (3) chromatin immunoprecipitation assay 
or electrophoresis mobility shift assay to confirm the binding of Sp1 to the 
dysbindin-1 promoter region, are needed to be addressed and carried out. 
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ROLE OF OXIDATIVE STRESS AND PEST SEQUENCE 










 In the previous chapter, the dysbindin-1 promoter activity was studied and 
results have shown (1) dysbindin-1 promoter activity was upregulated after H2O2 
treatment, and (2) this significant increase was reduced in cells treated with H2O2 
and WP631, a Sp1 inhibitor. These findings suggest Sp1 transcription binding 
sites found in the core promoter of dysbindin-1 could be involved in the regulation 
dysbindin-1 expression upon oxidative stress.  
 Following the study on dysbindin-1 gene expression in the previous 
chapter, the level of dysbindin-1 protein expression will be investigated in this 
chapter. Many studies have associated ROS and free radicals to the progression 
and development of neurodegenerative diseases such as schizophrenia and 
Alzheimer’s disease (AD) (Butterfield and Kanski, 2001; Rao and Balachandran, 
2002). Antioxidants that are able to reverse the adverse effects of free radicals 
are known to be potential neuroprotective agents (Floyd, 1999; Fang et al., 2002; 
Moosmann and Behl, 2002). In vitro experiments have also shown promising 
results involving antioxidants increasing neuronal viability, cell viability and 
reducing effects of oxidative damage (Brewer, 1997; Ricart and Fiszman, 2001). 
A H2O2 scavenger, phenyl- N- tert-butylnitrone (PBN) was used in this study to 
examine the effects of H2O2 induced oxidative stress on dysbindin-1 expression. 
PBN is found to display promising neuroprotective properties against free 
radicals in vitro and in vivo (Yue et al., 1992; Barth et al., 1996; Floyd and 
Hensley, 2002). PBN as a part of the family of nitrones can elicit its antioxidant 
role by converting free radicals with a reactive oxygen or carbon to nitroxide 
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radical species that are biochemically less reactive and more stable than its 
original state (Goldstein and Lestage, 2000).  
In addition, the effect of proteasome inhibitor and PEST sequence on 
dysbindin-1 protein expression under oxidative stress was also examined in this 
chapter. Ubiquitination is a protein posttranslational modification widely studied 
for the degradation of cytoplasmic and nuclear proteins by the proteasome 
(Jentsch, 1992; Yaron et al., 1998). Proteins targeted for degradation are 
recognized and labelled with ubiquitin moieties by E2-conjugating or/and E3-
ligating enzymes. These protein-ubiquitin complexes are then recognized by 
proteasome and degraded. Sequences that are rich in proline (P), glutamate (E), 
serine (S), and threonine (T) residues (i.e. PEST sequences) are found to act as 
a degradation signal (Roth et al., 1998; Shumway et al., 1999; Martinez et al., 
2003) and is present in the C-terminus of dysbindin-1 (Talbot et al., 2009). The 
larger the number of amino acid residues as mentioned above, the lower the 
hydrophobic index and, greater probability the sequence acting as a proteolytic 
signal. Using the PEST-Find algorithm, this probability is translated and reflected 
as a score. A general consensus has been reached and protein sequences with 
a score above 5 are regarded highly susceptible to degradation (Kakkar et al., 
1999; Singh et al., 2006). The PEST score for dysbindin-1A in rat is 10.48, 
consistent with the value reported by Talbot et al (Talbot et al., 2009). 
Together, with the discovery of a binding site for E3 ubiquitin ligase, 
TRIM32 in the C-terminus of dysbindin-1 (Locke et al., 2009), this protein could 
be regulated by proteasome and its PEST sequence. In this chapter, the effect of 
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PEST sequence under oxidative stress was investigated using SH-SY5Y human 
neuroblastoma cells that stably overexpress dysbindin-1A or dysbindin-1A 
without its PEST sequence. In addition, MG132, a proteasome inhibitor was used 
to further determine the effect of proteasome on dysbindin-1 protein degradation.  
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4.2 Materials and Methods 
4.2.1 Cells and Constructs  
Stable cell lines were generated to elucidate a possible effect of the PEST 
sequence of dysbindin-1 on protein expression. Total RNA was extracted from 
the hippocampus of normal rats, and the mRNA reverse transcribed to cDNA. A 
forward primer (5’-CAGTCTCGAGCGGATGCTGGAGACCCTGCGCGAG-3’) and 
reverse primer (5’-GTACGAATTCTTAAATGTCCTGAGTTGAGTC-3’) were used 
for the reverse transcription of full-length dysbindin-1A. A separate set of forward 
(5’-CAGTCTCGAGCGGATGCTGGAGACCCTGCGCGAG-3’) and reverse (5'-
GTACGAATTCTTACTTTCTGTCAGTGTTTAA-3') primers were used for the 
transcription of a truncated form of dysbindin-1A without its PEST sequence. 
Sequences underlined in the forward and reverse primers are restriction sites (i.e. 
XhoI and EcoRI respectively). Reverse transcription conditions were: 95oC for 30 
s, 40 cycles of 95oC for 30 s, 59oC for 30 s and 72oC for 30 s. The amplification 
process was completed with 72oC for 2 min. PCR product was resolved in 1% 
agarose gel at 100 V in 0.5 X TAE buffer that contained 0.5 µg/ml of ethidium 
bromide. 1kb DNA Ladder (Promega) was also loaded. After electrophoresis, the 
gel was observed under UV light, and bands that corresponded to dysbindin-1A 
with or without its PEST sequence were excised and purified using the QIAquick 
Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. The 
pIRES2-EGFP vector (Clontech) was used to construct a recombinant vector 
made by cloning dysbindin-1A with or without PEST sequence DNA into the 
XhoI/EcoRI sites found in the multiple cloning site (MCS) of pIRES2-EGFP. After 
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linearization, both DNA and vector contained sticky ends that were generated by 
XhoI and EcoRI. Ligation of the linearized dysbindin-1A DNA into the pIRES2-
EGFP was completed via the LigaFast™ Rapid DNA Ligation System (Promega) 
according to the manufacturer’s instructions. 
10 µl of ligation product was pipetted into 50 µl of chemically competent E. 
coli cells (Subcloning Efficiency™ DH5α™ competent cells, Invitrogen) and 
mixed gently. This mixture was incubated on ice for 30 min, 42oC water bath for 
20 s and immediately chilled on ice for 2 min. 1 ml of Lysogeny Broth (LB) 
medium (10 g of tryptone, 5 g of yeast extract and 10 g NaCl in 1 L of distilled 
water and autoclaved) was aseptically added into the vial and centrifuged at 225 
rpm, 37oC for 1 h. 200 µl of the purified transformation mix was added to a LB 
agar plate that contained 30 µg/ml of kanamycin and incubated overnight at 37oC. 
Colonies were selected and added to 5 ml of LB medium containing 30 µg/ml of 
kanamycin. The suspension was centrifuged at 225 rpm at 37oC overnight. 
Kanamycin-resistant DNA plasmids were extracted using the QIAprep Spin 
Miniprep Kit (Qiagen, #27104). SH-SY5Y cells (CRL-2266™, ATCC) were 
cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Gibco, Invitrogen). Samples with a density of 1.0 X 105 
cells/well were seeded into a 24-well plate and incubated at 37oC for 1 day. 
Transfections were carried out using Lipofectamine™ LTX and PLUS™ 
Reagents (Invitrogen) according to the manufacturer’s instructions. After 24 h 
transfection, cells were subcultured in a 6-well plate and 1 mg/ml of the selective 
reagent G418 (Invitrogen) was added. The growth medium (containing 1 mg/ml 
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of G418) was changed every 2 days for 10 days. Subsequently, 1 cell was plated 
into each 96 well via flow cytometry (Mo-Flo Legacy; Beckman-Coulter, FL, USA) 
to establish multiple clones. Cells were then subcultured into larger wells (i.e. 24-
well plate and 6-well plate) to obtain a stable cell line. 
 
4.2.2 Effect of oxidative stress on dysbindin-1A expression  
SH-SY5Y human neuroblastoma cells were cultured in 100 mm2 dishes, 
and divided into 4 groups: 1) Treatment with vehicle, 2) Treatment with 500 µM 
H2O2 for 24 h, 3) Treatment with 500 µM H2O2 and free radical scavenger, PBN 
(Sigma, MO, USA). SH-SY5Y cells were pretreated with 1 µM PBN for 45 min, 
followed by 500 µM H2O2 for 24 h, and 4) Treatment with PBN. Total proteins 
were extracted and analyzed by Western blot as described below. The means 
and standard errors were calculated and any possible significant differences 
were analyzed by 1 way ANOVA with Tukey’s multiple comparison post-hoc test 
(n=4 in each group). P < 0.05 was considered significant. 
 
4.2.3 Effect of proteasome inhibitor on dysbindin-1A expression  
The effect of proteasome inhibitor and PEST sequence on the expression 
of dysbindin-1A was examined. A total of 4 treatment groups were analyzed: 1) 
Treatment of SH-SY5Y cells stably overexpressing dysbindin-1A with vehicle, 2) 
Treatment of SH-SY5Y cells stably overexpressing dysbindin-1A with 0.5 µM 
MG132, 3) Treatment of SH-SY5Y cells stably overexpressing dysbindin-1A 
without its PEST sequence with vehicle, and 4) Treatment of SH-SY5Y cells 
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stably overexpressing dysbindin-1A without its PEST sequence with 0.5 µM 
MG132. Cells were treated for 24 h and harvested. Protein was extracted and the 
level of dysbindin-1A protein was analyzed by Western blot as mentioned below. 
The means and standard errors were calculated and any possible significant 
differences were analyzed by 1 way ANOVA with Tukey’s multiple comparison 
post-hoc test (n=3 in each group). P < 0.05 was considered significant. 
 
4.2.4 Effect of the PEST sequence of dysbindin-1A on protein expression 
after oxidative stress 
SH-SY5Y cells stably overexpressing dysbindin-1A, dysbindin-1A without 
its PEST sequence, or control vector were used. After reaching 80% confluence, 
cells were treated with 0 µM, 50 µM, or 500 µM of H2O2. Dilutions were freshly 
prepared from a 30% H2O2 stock. Treatment was carried out for 24 h and 
proteins were extracted and analyzed by Western blot analysis as mentioned 
below. The means and standard errors were calculated and any possible 
significant differences were analyzed by 1 way ANOVA with Tukey’s multiple 
comparison post-hoc test (n=4 in each group). P < 0.05 was considered 
significant. 
 
4.2.5 Western Blot analyses  
Proteins were extracted using the Mammalian Protein Extraction Reagent 
(M-PER, #78501, ThermoScientific, CA, USA) according to the manufacturer’s 
instructions, and the level of dysbindin-1A protein was analyzed by Western blot. 
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Using a 10% SDS polyacrylamide gel, 15 µg of proteins were separated via their 
molecular weight and electric charge and electrotransferred via the semi-dry 
transfer method (#170-3940, Bio-Rad Laboratories, CA, USA) onto a 
polyvinylidene difluoride (PVDF) membrane (Amersham Pharmacia Biotech, 
Little Chalfont, UK). The PVDF membrane was then incubated with 5% non-fat 
milk for 1 h at room temperature to block non-specific binding sites. Thereafter, it 
was probed with a rabbit polyclonal antibody to the N-terminus of dysbindin-1 
(diluted 1:250 in Tris-buffered saline [TBS]) (#sc-67171, Santa Cruz 
Biotechnology, CA, USA) overnight at 4°C. Following an overnight incubation, 
excess unbound primary antibody was washed with 0.1% Tween-20 in TBS, 6 
times at 5 min interval with gentle agitation. The membrane was then incubated 
with a secondary antibody, horseradish peroxidase-conjugated anti-rabbit 
immunoglobulin IgG (Amersham Pharmacia Biotech) to enhance its signal for 1 h 
at room temperature. Excess unbound secondary antibody was removed via 6 
washes of 0.1% Tween-20 in TBS at 5 min interval with gentle agitation. Protein 
visualization was then carried using an enhanced chemiluminescence kit (Pierce, 
IL, USA) according to the manufacturer’s instructions. After exposure, the blot 
was stripped of antibodies and re-probed with a mouse monoclonal antibody to 
β-actin as a loading control (diluted 1:10000 in TBS at 4°C, Sigma). To test for 
transfection efficiency, the membrane was re-probed with an antibody to the co-
expressed green fluorescent protein (GFP) (diluted 1:10000 in TBS at 4°C, 
Novus Biologicals, Cambridge, UK). Densitometric analysis of the bands in 
Western blots was performed using GelPro software (Media Cybernetics, MD, 
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USA) and any possible significant differences in the normalized mean densities 
were analyzed using 1 way ANOVA with Tukey’s multiple comparison post-hoc 

















Figure 4.3.1. Analysis of untransfected SH-SY5Y cells treated with or without PBN 24 h 
after 500 µM H2O2 treatment. A: Western blots showing: 1) Untreated SH-SY5Y cells (lanes 1-4), 
2) SH-SY5Y cells treated with 500 µM H2O2 (lanes 5-8), 3) SH-SY5Y cells treated with the free 
radical scavenger, PBN, 45 min prior to treatment with 500 µM H2O2 (lanes 9-12), 4) Untreated 
SH-SY5Y cells (lanes 13-16), and 5) SH-SY5Y cells treated with the free radical scavenger, PBN 
for 45 min (lanes 17-20). B: Dysbindin-1 normalized to β-actin. Decrease in dysbindin-1 protein 
was detected 1 day after 500 µM H2O2 treatment. In contrast, dysbindin-1 protein levels were not 
affected if cells were pre-treated with PBN for 45 min prior to H2O2 treatment, indicating the role 
of reactive oxygen species in dysbindin-1 degradation. No significant difference was observed 




































































shown. * indicates significant difference (P < 0.05) compared to control. # indicates significant 
difference compared to SH-SY5Y cells treated with 500 µM H2O2. 
 
The affinity purified rabbit polyclonal antibody that recognized the N-
terminus (1-90 amino acid of the N-terminus of the human dysbindin origin) of 
dysbindin isoforms detected a single band at 50 kDa (Figure 4.3.1A). This band 
size of dysbindin-1A is higher than the predicted molecular weight of 40 kDa 
(Talbot et al., 2004). Recent reports have depicted dysbindin-1A with a higher 
molecular weight that ranges from 48-50 kDa. This could be due to the highly 
acidic nature of the C-terminus of dysbindin-1A (Talbot et al., 2004) or 
posttranslational modifications such as ubiquitination and/or phosphorylation 
(Talbot et al., 2004; Locke et al., 2009). A single band detected also dismisses 
the possibility of degradative product formed from improper handling of tissue 
lysate for Western blot. 
A significant decrease to 0.66-fold in dysbindin-1A protein expression was 
detected in SH-SY5Y human neuroblastoma cells after treatment with 500 µM 
H2O2, compared to vehicle (Figures 4.3.1A and B). This decrease was absent in 
SH-SY5Y cells that were pre-incubated with the free radical scavenger PBN prior 
to H2O2 treatment (Figures 4.3.1A and B). No significant difference in dysbindin-
1A protein level was observed between SH-SY5Y cells treated with PBN and 















Figure 4.3.2. Analysis of SH-SY5Y cells treated with or without MG132 after 24 h. A: 
Western blots showing: 1) SH-SY5Y cells overexpressing full-length dysbindin-1, treated with 
vehicle (Lanes 1-3), 2) SH-SY5Y cells overexpressing full-length dysbindin-1, treated with 0.5 µM 
MG132 (Lanes 4-6), 3) SH-SY5Y cells overexpressing dysbindin-1A without its PEST sequence 
treated with vehicle (Lanes 7-9), 4) SH-SY5Y cells overexpressing dysbindin-1 without its PEST 





































































that stably overexpress full-length dysbindin-1 showed significantly greater protein expression 
after treatment with MG132, compared to vehicle controls, or cells expressing the protein without 
its PEST sequence, indicating an effect of the proteasome inhibitor and the PEST sequence, in 
dysbindin-1 protein level. The mean +SE are shown. * indicates significant difference (P < 0.05) 
compared to SH-SY5Y cells overpressing full-length dysbindin-1 treated with vehicle. # indicates 
significant difference compared to SH-SY5Y cells overpressing full-length dysbindin-1 treated 
with MG132. Abbreviations: FL: SH-SY5Y cells overexpressing full-length dysbindin-1A, WP: SH-
SY5Y cells overexpressing dysbindin-1A without its PEST sequence. 
 
To study the effects of proteasome and the PEST sequence of dysbindin-
1A in its degradation, SH-SY5Y cells that stably overexpress full-length 
dysbindin-1A or dysbindin-1A without its PEST sequence were treated with 
MG132. A significant 2.73-fold increase in dysbindin-1A protein expression was 
detected in SH-SY5Y cells that overexpress full-length dysbindin-1A after MG132 
treatment, compared to vehicle controls (Figures 4.3.2A and B). In contrast, no 
increase was found in SH-SY5Y cells that overexpress dysbindin-1A without its 
PEST sequence after MG132 treatment (Figures 4.3.2A and B).  
 
4.3.3 Effect of the PEST sequence of dysbindin-1A on protein expression 






































































Figure 4.3.3. Western blot analysis of SH-SY5Y cells transfected with dysbindin-1A, or 
without its PEST sequence or vector control. A, C, E: Transfected or vector control SH-SY5Y 
cell lines treated with 0 µm, 50 µm, and 500 µm H2O2, respectively. B, D, F: Dysbindin-1 
normalized to β-actin. Cells overexpressing full-length dysbindin-1 (FL) showed significantly 
greater degradation after high level of oxidative stress induced by 500 µm H2O2, than cells 
expressing dysbindin-1 without its PEST sequence (WP). The expression level of exogenous 
dysbindin-1A is negligible in the control condition. The mean +SE are shown. * indicates 
significant difference (P < 0.05) compared to SH-SY5Y cells overexpressing vector control. # 
indicates significant difference compared to SH-SY5Y cells overexpressing full-length dysbindin-1. 
Abbreviations: FL: SH-SY5Y cells overexpressing full-length dysbindin-1, WP: SH-SY5Y cells 
overexpressing dysbindin-1 without its PEST sequence. V: control SH-SY5Y cells overexpressing 
empty vector and depict endogenous expression of dysbindin-1.  
 
Dysbindin-1A expression observed in the vector control depicts the basal 
level of dysbindin-1 found in SH-SY5Y cells, and any significant increase in the 
dysbindin-1 expression is hence mainly due to overexpressed dysbindin-1A 
levels. Significantly greater dysbindin-1 expression was found in SH-SY5Y cell 













PEST sequence, compared to vector expressing controls (Figures 4.3.3A and B). 
Likewise, significantly greater dysbindin-1 expression was observed in cells 
expressing full-length dysbindin 1 or dysbindin-1 without its PEST sequence, 
after treatment with 50 µM H2O2, compared to vector controls (Figures 4.3.3C 
and D). After exposure to 500 µM of H2O2, levels of dysbindin-1 were significantly 
greater in SH-SY5Y cells expressing dysbindin-1 without its PEST sequence, 
compared to cells expressing full-length dysbindin-1, and vector controls (Figures 










In this chapter, the effects of oxidative stress and free radicals on 
dysbindin-1 protein expression were elucidated. Normal SH-SY5Y cells treated 
with the free radical scavenger PBN showed less degradation of dysbindin-1 
protein after H2O2 induced oxidative stress than those without PBN, indicating the 
role of reactive oxygen species in dysbindin-1 degradation. This effect is likely at 
the protein level, since oxidative stress has shown to increase mRNA expression 
of dysbindin-1 through action at the core promoter, as observed in the previous 
chapter. An increase in dysbindin-1 gene expression could be a compensatory 
mechanism possibly through the activation of riboswitches in response to a mark 
reduction in dysbindin-1 protein level after oxidative stress (Cheah et al., 2007). 
Interestingly, dysbindin-null (sdy) mice are characterized to have reduced levels 
of H2O2 scavenging peroxiredoxins, a finding that is also observed in 
schizophrenic subjects (Gokhale et al., 2012). The above finding indicates that 
dysbindin-1 protein degradation is increased by oxidative stress, and the 
presence of an antioxidant such as PBN could modulate its degradation. It is also 
interesting to note that due to the spin-trapping properties of PBN, it could 
prevent the excessive accumulation of free radicals and thus display protective 
characteristics against excitotoxicity and oxidative stress (Lancelot et al., 1997). 
Besides, being proven as a possible therapy against disease related due to 
excessive free radical production (e.g. aging and stroke) (Kotake, 1999), PBN 
have shown to be a compound effective against extrapyramidal side effects due 
to long-term antipsychotic drugs dependence (Daya et al., 2011).  
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Since the increase in dysbindin-1 mRNA expression after oxidative stress 
could not account for the decrease in dysbindin-1 protein levels observed, 
posttranslational modifications such as ubiquitination and phosphorylation could 
promote the degradation of dysbindin-1A, and thus explain its reduction (Locke et 
al., 2009). Dysbindin-1A and -1C contain the PEST sequence in their C-terminus 
and we hypothesize that the presence of these sequences promotes degradation 
in a proteasome dependent manner. The effects of PEST sequence and 
proteasome inhibitor on dysbindin-1 protein expression were then determined in 
this chapter. A PEST sequence often marks a protein for proteasomal 
degradation (Rechsteiner and Rogers, 1996; Garcia-Alai et al., 2006); for 
example, it is critical for oxidative-stress induced phosphorylation-dependent 
degradation of the protein IκBα (Schoonbroodt et al., 2000). Phosphorylation at 
kinases sites (Talbot et al., 2009) apparent in the PEST domain of dysbindin-1 
suggests a change in conformation of proteins, recognizable by the ubiquitin-
proteasome which may be responsible for its degradation (Rechsteiner and 
Rogers, 1996; Garcia-Alai et al., 2006). Moreover, the PEST sequence of 
dysbindin-1 contains a recognition site for TRIM32, which is an E3 ubiquitin 
ligase involved in the ubiquitin-proteasome degradation system (Locke et al., 
2009). A possible role of proteasome in degradation of dysbindin-1 proteins was 
studied in vitro using a proteasome inhibitor, MG132 while a role of PEST 
sequence in degradation was examined, using stable cell lines that overexpress 
full-length dysbindin-1 or truncated dysbindin-1 isoform without its PEST 
sequence. Cells that overexpress dysbindin-1A showed a 2.73-fold increase in 
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expression after treatment with the proteasome inhibitor, MG132. This suggests 
that the protein turnover rate of full length dysbindin-1 is dependent on 
proteasome as a significant increased dysbindin-1 expression is observed after 
cells were treated with a proteasome inhibitor. Evidence also showed that 
dysbindin-1 protein is degraded in a PEST sequence dependent manner. Cells 
that overexpress dysbindin-1A without its PEST sequence showed no increase in 
expression. This finding not only ascertained that the truncated dysbindin-1A has 
been amplified and transfected successfully; it also suggests that dysbindin-1A 
devoid of its PEST sequence is less susceptible to protein degradation. It is 
noted that cells overexpressing the truncated protein treated with or without 
MG132 express reduced dysbindin-1A levels as compared to cells 
overexpressing full length dysbindin-1A treated with MG132. This finding could 
be due to lower transfection efficiency in cells that overexpress the truncated 
protein than cells that overexpress its full length isoform (Figure 4.3.2C). Taken 
together, converging findings in this study propose that dysbindin-1 is degraded 
in a proteasome and PEST sequence manner.  
The effect of oxidative stress on dysbindin-1 protein with or without its 
PEST sequence was further elucidated. At 0 µM and 50 µM H2O2, cells 
overexpressing full-length dysbindin-1A and cells overexpressing dysbindin-1A 
without its PEST sequence showed no difference in dysbindin-1A expression. At 
higher concentration of 500 µM H2O2, significantly greater dysbindin-1A protein 
expression was found in SH-SY5Y cells overexpressing dysbindin-1A without its 
PEST sequence, compared to those expressing its full-length protein. These 
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results indicate that cells expressing dysbindin-1A without its PEST sequence 
were more resistant to H2O2 induced damage than the native protein; and also 
highlight the role of the PEST sequence in mediating dysbindin-1 protein 
degradation after oxidative stress. Similar to the truncated dysbindin-1 protein, 
short-lived proteins such as HCLS1-associated protein X-1 (Hax-1) (Li et al., 
2012) and heat shock transcription factor 2 (HSF2) (Xing et al., 2010) with its 
PEST sequence deleted were more stable with slower turnover rates.  
Despite previous and present studies showing convincing evidence that 
dysbindin-1 are degraded in a proteasome and PEST sequence dependent 
manner, the possibility of a calpain-dependent degradation pathway should not 
be dismissed. The production of ROS induced by H2O2 can increase Ca2+ and 
activate Ca2+-dependent proteases; calpain (Hill et al., 2008; Rasbach et al., 
2008; Wei et al., 2009). Proteins containing PEST sequence can also bind Ca2+, 
and such sites are likely targets for calpain to cleave, resulting in its degradation 
(Shumway et al., 1999; Rasbach et al., 2008).  
  
Chapter 5 













ROLE OF KAINATE EXCITOTOXICITY ON DYSBINDIN-1 


















 In previous chapters (Chapter 3 and 4), the effects of oxidative stress on 
dysbindin-1 gene and protein expression in vitro were studied. Present results 
found at the gene level upon oxidative stress, DTNBP1 is regulated by its core 
promoter (i.e. Sp1 binding sites) while dysbindin-1 protein degradation is 
modulated by its PEST sequence found in its C-terminus.  
 In this chapter, the role of oxidative stress on dysbindin-1 expression in 
vivo was examined. Extensive studies on subjects with schizophrenia have found 
a strong association between oxidative stress and schizophrenia. Specifically, 
reduced antioxidant enzymes levels (e.g. catalase, glutathione peroxidase, and 
superoxide dismutase) (Reddy et al., 1991; Ranjekar et al., 2003; Zhang et al., 
2010), lower levels of plasma and serum antioxidants (i.e. albumin, bilirubin, 
thioredoxin, and uric acid) (Reddy et al., 2003; Zhang et al., 2009), and elevated 
levels of plasma and serum lipid peroxidative products (i.e. thiobarbiturate 
reactive substances and malondialdehyde) (McCreadie et al., 1995; Zhang et al., 
2006) were observed in schizophrenia patients. Taken together, these findings 
indicate an imbalance in redox regulation could play an imperative role in the 
onset and pathogenesis of schizophrenia. Interesting, it is noteworthy that 
several animal studies on oxidative stress displayed behavioral abnormalities 
and cognition dysfunction similar to symptoms observed in schizophrenia 
patients (Cabungcal et al., 2007; Steullet et al., 2010). Cabungal et al. showed 
through many behavioral studies, one of which; the homing hole board task that 
despite the aid of visual and/or olfactory cues, rats exposed to oxidative stress in 
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the early prenatal stage took more time to find the path (out of five possibilities) 
to its home cage as compared to vehicle-treated rats (Cabungcal et al., 2007). 
Together, oxidative stress is likely to exert an adverse effect on spatial learning 
and memory ability in early development. In a recent study, Steullet et al. have 
also found oxidative stress resulted in reduced neural oscillation in the 
hippocampus of young male rats, and abnormalities in response to object 
recognition task (Steullet et al., 2010). Hence, in this chapter, changes in 
dysbindin-1 expression in the hippocampus will be the main focus as there is 
much emphasis of an impaired cognitive function seen in schizophrenia patients 
and its pertinent role in learning and memory (Jarrard, 1993; Chambers et al., 
1996; Bruel-Jungerman et al., 2007). Moreover, the hippocampus is known to be 
particularly vulnerable to oxidative stress and excitotoxicity (Jellinger, 2010). 
To elucidate the effect of oxidative stress and excitotoxicity on dysbindin-1 
expression, the KA-mediated neurodegenerative model was used in this study. 
KA has shown to depict an increase in ROS and RNS which in turn lead to 
mitochondrion dysfunction and trigger apoptosis in neurons found in different 
brain regions (Wang et al., 2005a). It is also an established experimental model 
in inducing seizures and selective neuronal damage in susceptible limbic 
structures (i.e. CA3 of the hippocampus) (Schwob et al., 1980; Ben-Ari, 1985). 
KA could be administered systemically (i.e. subcutaneously, intravenously, and 
intraperitoneally), however studies showed that only a small amount of the 
injected KA could reach its receptors found in the brain (Berger et al., 1986). In 
this study, KA-mediated excitotoxicity was carried out via intracerebroventricular 
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injection as this route of administration induces more consistent lesioned sites in 
the hippocampus (Ong et al., 1999). Unilateral KA injection was carried out on 
the right lateral ventricle to provide a more distinct comparison between its 
ipsilateral and contralateral hippocampus upon neurodegeneration. Rats were 
injected with saline and used as a vehicle control in this study.  
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5.2 Material and Methods  
5.2.1 Kainate injections 
Wistar rats of approximately 200g each were ordered and purchased from 
the Centre of Animal Resources (CARE). The rats were each deeply 
anesthetized with 0.4 ml (0.2 ml/100g body weight) of an old rat anesthesia 
cocktail consisting ketamine (75 mg/kg), xylazine (10 mg/kg), and sterile water. 
1.0 µl of KA (1 mg/ml dissolved in saline, Tocris, MN, USA) was stereotaxically 
injected into the right lateral ventricle of the rat brain as previously illustrated (Kim 
and Ong, 2009). After surgery, animals were assessed for the severity of their 
seizure based on the Racine scale (Racine, 1972) and all KA-injected rats were 
found to have scored 3 or above. Post-operative care was carried out to minimize 
animal suffering. All procedures pertaining to the animal study conducted were 
certified by the Institutional Animal Care and Use Committee (IACUC), National 
University of Singapore.  
 
5.2.2 Immunohistochemistry 
A total of sixteen rats, consisting of four 1 day saline-treated controls, four 
2 weeks saline-treated controls, four 1 day post-KA, and four 2 weeks post-KA 
injected rats were used for this study. They were deeply anesthetized 
intraperitoneally (please refer to Chapter 5.2.1 for more details on the type of 
anesthesia used) and were perfused via the left cardiac ventricle with Ringer’s 
solution (i.e. 8.5 g NaCl, 0.25 g KCl, 0.3 g CaCl2, 0.2 g NaHCO3 dissolved in 1 L 
of distilled water) to allow drainage of blood, followed by 4% paraformaldehyde in 
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0.1 M phosphate buffer (pH 7.4) for fixation. 100 µm thin sections of the fixed 
brain were cut coronally using a vibrating microtome. To remove any traces of 
paraformaldehyde, sections were washed for 3 h, 5 min interval with gentle 
agitation in phosphate-buffered saline (PBS). The sections were then incubated 
overnight with the goat polyclonal antibody to dysbindin-1 (1:250 of SC-46931, 
Santa Cruz Biotechnology). To remove any unbound primary antibody, sections 
were washed 6 times, 5 min interval with gentle agitation in PBS and incubated 
for 1 h at room temperature in 1:2000 dilution of biotinylated horse anti-goat IgG 
secondary antibody (Vector, CA, USA). Sections were then incubated with an 
avidin-biotinylated horseradish peroxidase complex for 1 h at room temperature, 
and visualized with 0.05% of 3, 3-diaminobenzidine tetrahydrochloride (DAB) 
solution in Tris buffer containing 0.05% H2O2 treatment for 10 min. The reaction 
was halted with 4 washes of Tris buffer, 5 min intervals with gentle agitation. 
Stained sections were mounted on gelatinized glass slides and lightly 
counterstained with methyl green for better visualization (0.25% solution in 0.1 M 
acetate buffer, pH 4.8, Sigma). Control sections were incubated with antigen-
absorbed antibody prepared by pre-incubating 200 µg/mL immunizing peptide 
with dysbindin-1 antibody overnight, instead of primary antibody. Cell counts 
were performed to quantify the mean number of dysbindin-1 labeled neurons in 
the DG, CA1 and CA3 regions of saline-treated controls, 1 day and 2 weeks 
post-KA-injected rats. Four sections from each region of each rat were quantified. 
The mean number of positively labelled neurons and its standard error were 
calculated and any possible significant differences between KA-injected and 
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saline-control groups were analyzed using the Student’s t-test. P < 0.05 was 
considered significant. 
 
5.2.3 Real time RT-PCR analyses 
A total of eighteen rats, consisting of six saline-treated controls, six 1 day 
post-KA, and six 2 weeks post-KA injected rats, were used for this study. 
Decapitation was carried out after the rats were deeply anaesthetized (please 
refer to Chapter 5.2.1 for more details on the type of anesthesia used), certified 
by an absence of tail, cornea, and toe-pinch reflexes. The right HF ipsilateral to 
the injection was harvested and kept in RNAlater® (Ambion, TX, USA), 
immediately frozen in liquid nitrogen, and kept at -80oC for preservation until 
further analysis. Trizol reagent (Invitrogen) was used for total RNA extraction, 
according to the manufacturer’s protocol. The extracted RNA was then purified 
using the RNeasy® MiniKit (Qiagen). Thereafter, samples were reverse 
transcribed via RT-PCR and the amplified transcripts were analyzed by real time 
RT-PCR as mentioned above, except that probes for rat Dtnbp1 and β-actin 
(Rn01434739_m1, #4352340E respectively) were used. The means and 
standard errors were calculated and any possible significant differences between 
the KA-injected HF and its saline-control were determined, using the Student’s t-










5.2.4 Western blot analyses 
A total of sixteen rats, consisting of four 1 day saline-treated control, four 1 
day post-KA, four 2 weeks saline-treated control, and four 2 weeks post-KA 
injected rats, were used in this study. The HF (ipsilateral to KA injection) was 
harvested and immediately frozen in liquid nitrogen, and kept at -80oC for 
preservation until further analysis. Total protein was extracted using the T-PER® 
Tissue Protein Extraction Reagent (Pierce) according to the manufacturer’s 
instructions while its protein concentration was determined using the Bio-Rad 
Protein Assay (Bio-Rad). The expression level of dysbindin-1 was analyzed by 
Western blot as mentioned above. A goat polyclonal antibody to dysbindin-1 
(diluted 1:200 in Tris-buffered saline [TBS]) (#sc-46931, Santa Cruz 
Biotechnology) which recognizes the C-terminus of dysbindin-1 was used. The 
mean densities and standard errors were calculated and any possible significant 
differences were analyzed by 1 way ANOVA with Tukey’s multiple comparison 












5.3.1 Effect of oxidative stress on dysbindin-1 localization in the 
hippocampal formation 
 
Figure 5.3.1.1. Dysbindin-1 immunoreactivity in the HF of rats post 1 day KA injection. A: 
dentate gyrus of a saline-treated rat, showing light immunoreactivity to dysbindin-1 (arrows). B: 
field CA3 of a saline-treated rat, showing light immunoreactivity to dysbindin-1 (arrows). C: field 
CA1 of a saline-treated rat, showing light immunoreactivity to dysbindin-1 (arrows). D: dentate 
gyrus from a 1 day post-KA injected rat, showing scattered positive cells in the subgranular zone 
(arrows). E: field CA3 from a 1 day post-KA injected rat, showing decreased dysbindin-1 labelling 
at the injection site (asterisk). F: field CA1 from a 1 day post-KA injected rat, showing light 
immunoreactivity to dysbindin-1 (arrows). G: dentate gyrus from a 1 day post-KA injected rat 
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contralateral to injection, showing scattered positive cells in the subgranular zone (arrows). H: 
field CA3 from a 1 day post-KA injected rat contralateral to injection, showing increased 
dysbindin-1 labelling in scattered neurons (arrows). I: field CA1 from a 1 day post-KA injected rat 
contralateral to injection, showing large numbers of immunopositive pyramidal neurons (arrows). 
J: dentate gyrus of a control section incubated with antigen-absorbed antibody showing only 
background staining. K: field CA3 of a control section, showing background staining. L: field CA1 




Figure 5.3.1.2. Dysbindin-1 immunoreactivity in the HF of rats 2 weeks post KA injection. A: 
dentate gyrus from a 2 weeks post-saline injected rat ipsilateral to injection, showing light 
immunoreactivity to dysbindin-1 (arrows). B: field CA3 from a 2 weeks post-saline injected rat 
ipsilateral to injection, showing light immunoreactivity to dysbindin-1 (arrows). C: field CA1 from a 
2 weeks post-saline injected rat ipsilateral to injection, showing light immunoreactivity to 
dysbindin-1 (arrows). D: dentate gyrus from a 2 weeks post-KA injected rat ipsilateral to injection, 
showing decreased dysbindin-1 labelling (arrows). E: field CA3 from a 2 weeks post-KA injected 
rat ipsilateral to injection, showing decreased dysbindin-1 labelling (arrows). F: field CA1 from a 2 
weeks post-KA injected rat ipsilateral to injection, showing no visible change in dysbindin-1 
labelling (arrows). Scale = 20µm. 
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Figure 5.3.1.3. Number of positive dysbindin-1 labelled neurons in the rat HF, 1 day and 2 
weeks after KA or saline treatment ipsilateral to injection. A: dentate gyrus from 1 day post-
KA injected rats showed an increase in dysbindin-1 labelling, compared to 1 day post-saline 
injected rats, while the dentate gyrus from 2 weeks post-KA injected rats showed a decrease in 
dysbindin-1 labelling, compared to 2 weeks post-saline injected rats. B: CA3 from 1 day and 2 
weeks post-KA injected rats showed a decrease in dysbindin-1 labelling, compared to their 
respectively saline controls. C: CA1 from 1 day post-KA injected rats showed an increase in 
dysbindin-1 labelling, compared to 1 day post-saline injected rats, while the CA1 from 2 weeks 
post-KA injected rats showed no significant change in dysbindin-1 labelling, compared to 2 weeks 
post-saline injected rats. The mean +SE are shown. * indicates significant difference (P < 0.01) 
as compared to its respective saline control. 
 
The distribution of dysbindin-1 positive cells after KA treatment was then 
analyzed by immunohistochemistry. Light staining was observed on granule 
neurons (Figure 5.3.1.1A) and neurons of field CA3 (Figure 5.3.1.1B) and CA1 
(Figure 5.3.1.1C) in the normal rat hippocampus. At 1 day post-KA injection, 
increased staining was observed in subgranular zone and the adjacent 
polymorph layer of the dentate gyrus (DG) (Figure 5.3.1.1D) and in field CA1 
(Figure 5.3.1.1F), while decreased immunoreactivity was observed in field CA3 
(Figure 5.3.1.1E) relative to saline controls on the HF ipsilateral to the KA 
injection. Dense dysbindin-1 immunolabelled neurons were also observed in the 
DG (Figure 5.3.1.1G), CA3 (Figure 5.3.1.1H) and CA1 (Figure 5.3.1.1I) on the 
contralateral HF. Control sections were incubated with antigen-absorbed 
antibody and showed background staining and this confirmed the specificity of 
the antibody (Figures 5.3.1.1J, K and L). The immunoreactivity of dysbindin-1 
was quantified. At 1 day post-KA injection, a significant 2.70- (Figure 5.3.1.3A) 
and 4.39-fold (Figure 5.3.1.3C) increase in the number of dysbindin-1 positive 
neurons relative to saline controls were found in the DG and CA1 respectively, 
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while a significant 0.19-fold (Figure 5.3.1.3B) decrease was observed in the CA3 
in the HF ipsilateral to the KA injection.  
At 2 weeks post-KA injection, as compared to saline controls (Figures 
5.3.1.2A-C), decreased immunoreactivity was observed in the DG and CA3 
(Figures 5.3.1.2D and E), whereas no visible change in dysbindin-1 labelling in 
the CA1 (Figure 5.3.1.2F) ipsilateral to the KA injection. Significant decrease in 
the number of dysbindin-1 labelled neurons to 0.36-fold and 0.14-fold in the DG 
and CA3 (Figures 5.3.1.3A and B), while no significant change in the CA1 (Figure 
5.3.1.3C), was found in the ipsilateral HF relative to saline controls at this time. 
 
5.3.2 Effect of oxidative stress on dysbindin-1 mRNA and protein 







































Figure 5.3.2.1. Dysbindin-1 expression in the rat HF 1 day after KA treatment. A: Fold 
change in dysbindin-1 mRNA level. B: Dysbindin-1 protein normalized to β-actin after 2 weeks 
KA treatment. KA treatment results in no signifcant change in dysbindin-1 mRNA and protein 
expression at 1 day post-KA. The mean +SE are shown. C: Western blots showing: 1) 
Homogenates from saline-treated control hippocampus (lanes 1-4), 2) Homogenates from the 
hippocampus, 1 day after intracerebroventricular KA injection (lanes 5-8).  
 
No change in DTNBP1 mRNA expression was found by real time RT-PCR 
in the HF at 1 day after excitotoxicity induced by KA (Figure 5.3.2.1A). The 
affinity purified polyclonal antibody to dysbindin-1 showed a single band at 
approximately 33 kDa in the saline-treated and KA-treated rat HF in Western 
blots and this corresponds to the molecular weight of dysbindin-1C (Talbot et al., 
2009). No significant difference in the dysbindin-1 protein expression was 
detected at 1 day after KA injury compared to saline controls (Figures 5.3.2.1B 





















































Figure 5.3.2.2. Dysbindin-1 expression in the rat HF 2 weeks after KA treatment. A: Fold 
change in dysbindin-1 mRNA level 2 weeks after KA treatment. B: Dysbindin-1 protein 
normalized to β-actin after 2 weeks KA treatment. KA treatment results in decreased expression 
at 2 weeks postinjection. The mean +SE are shown. *indicates significant difference (P < 0.05) 
compared to its respective saline control. C: Western blots showing: 1) Homogenates from 
saline-treated control hippocampus (lanes 1-4), 2) Homogenates from the hippocampus, 2 weeks 
after intracerebroventricular KA injection (lanes 5-8). 
 
A significant decrease in dysbindin-1 mRNA expression to 0.51-fold 
(Figure 5.3.2.2A) was found in the HF at 2 weeks post-KA treatment, and was 
accompanied by significantly reduced dysbindin-1 protein level to 0.57-fold, 













































In vivo studies were carried out in parallel to determine possible changes 
in dysbindin-1 expression after KA excitotoxicity. Many studies have shown 
increased oxidative stress after KA induced excitotoxicity (Nakaso et al., 1999; 
Ong et al., 2000; Ibarretxe et al., 2006; Zheng et al., 2011), and protein and lipid 
oxidative markers were found to persist even 24 h after KA injury (Gluck et al., 
2000). Furthermore, antioxidant enzymes such as glutathione and superoxide 
dismutase were reduced post-KA treatment (Wang et al., 2005a). These findings 
indicate that KA excitotoxicity could have some features of H2O2 induced 
oxidative stress.  
At 1 day after KA injection, immunohistochemical analyses showed 
increase in dysbindin-1 expression in the DG and CA1, but loss of 
immunoreactivity in neurons in the CA3, and real time RT-PCR and Western blot 
analyses showed no significant change in dysbindin-1 mRNA expression or 
protein expression. Increase in expression could be due to the effect of oxidative 
stress on the core promoter activity of dysbindin-1, as shown by our in vitro 
studies. An upregulation of dysbindin-1 could suggest an early compensatory 
response in those areas to acute oxidative stress and/or activation of synaptic 
NMDA receptors, which can acutely boost antioxidant defenses (Papadia et al., 
2008). An increase in dysbindin-1 expression was also found in the HF 
contralateral to KA injection. Compared to the structures ipsilateral to the 
injection, neurons in the contralateral CA1 and DG showed much higher 
dysbindin-1 immunoreactivity 1 day after KA injection. While KA promotes death 
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of vulnerable neurons locally, it is possible that milder excitotoxicity exerts 
remotely triggers a protective mechanism and, in the case of the HF, activates 
commissural projections from CA3 and the DG hilus to the contralateral HF 
(Raisman G, 1965). 
In contrast to the DG and CA1, loss of dysbindin-1 immunoreactivity was 
observed in the CA3 ipsilateral to KA injection. This variability in KA vulnerability 
could be due to a higher distribution of AMPA/kainate receptors and sensitivity to 
Ca2+ induced cellular injury in CA3 pyramidal neurons than granule cells in the 
dentate gyrus (McGeer and McGeer, 1982; Wang et al., 2005b). Together, an 
increase in dysbindin-1 in the DG and CA1, but decrease in CA3, could account 
for no net change in dysbindin-1 mRNA and protein levels at 1 day post-KA 
injection. 
Unlike results observed at 1 day post-KA, decreased dysbindin-1 gene 
and protein expression were found at 2 weeks post-KA injection. This reduction 
was also evident in the postmortem HF of schizophrenia cases (Talbot et al., 
2004; Talbot et al., 2011). Decreased dysbindin-1 immunolabelling was observed 
in DG and CA3 while no significant change was observed in the CA1. It is 
possible that high level of oxidative stress after KA especially in the CA3 (Ong et 
al., 2000) could result in increased proteasomal degradation of dysbindin-1 
protein, as found by our in vitro studies. Interestingly, dysbindin-1 protein 
expression found in our immunohistochemical study after 2 weeks post-KA 
showed a trend akin to the DTNBP1 gene expression in the DG, CA1 and CA3 of 
schizophrenia cases reported by Weickert et al (2008). Taken together, besides 
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a proteasome-dependent degradation pathway, decreased DTNBP1 transcription 
may also be involved in decreased dysbindin-1 protein expression reported after 
long term exposure to oxidative stress.  
Since a majority of the brain dysbindin may exist as a biogenesis 
lysosome-related organelles complex-1 (BLOC-1) (Ghiani et al., 2010), it may 
also be important to determine whether other subunits of the BLOC-1 complex 
are affected by oxidative stress or excitotoxicity in future studies. Intriguingly, 
converging evidence suggests dysbindin binding partners such as JARID2, 
MUTED, and ATXN1 may be associated with schizophrenia. Specifically, repeat 
polymorphism in JARID2 (Pedrosa et al., 2009), multiple SNPs in MUTED 
(Straub RE, 2005), mutation in ATXN1 (Joo et al., 1999; Duenas et al., 2006) 
have been associated to the added risk and/or pathogenesis of schizophrenia. 
Moreover, in the dysbindin-1 null model (sdy), reduced dysbindin-1A and 
dysbindin-1C expression was accompanied with a decrease in other subunits 
(e.g. MUTED and pallidin) of the BLOC-1 complex (Li et al., 2003). Hence, future 
studies on the interactions and effects of different BLOC-1 subunits after 
oxidative stress could allow a better understanding on the etiology and 






























In conclusion, this thesis has investigated the effects of dysbindin-1 gene 
and protein expression in vitro and in vivo after oxidative stress. 
In Chapter 3, the effect of oxidative stress on the activity of dysbindin-1 
core promoter was studied in vitro. Dual luciferase reporter assay results have 
shown an upregulation in dysbindin-1 core promoter activity after H2O2 induced 
oxidative stress and this induction was abolished by a Sp1 inhibitor, WP631. This 
suggests an increase in dysbindin-1 gene expression could be mediated by the 
activation of Sp1 binding sites present in its core promoter. Hence, this finding 
could serve as one of the possible means in restoring dysbindin-1 levels in 
schizophrenia patients. However, to validate Sp1 as an activator of dysbindin-1 
promoter, further studies such as site-specific mutagenesis of the Sp1 promoter 
and siRNA knockdown experiments are needed to be carried out. 
In Chapter 4, the role of PEST sequence and proteasome inhibitor on 
dysbindin-1 protein expression was explored. Endogenous dysbindin-1 
expression in SH-SY5Y cells after oxidative stress was significantly reduced but 
was restored after treatment with a free radical scavenger, PBN prior to oxidative 
stress. This result suggests the decrease in dysbindin-1 protein expression as 
seen in schizophrenia patients (Talbot et al., 2004; Talbot et al., 2012), could be 
due to the accumulation of excessive free radicals. A recent study has found 
PBN to be a promising agent against extrapyramidal side effects due to long-
term antipsychotic drugs dependence (Daya et al., 2011). Hence, antioxidants 
such as PBN could present itself as a promising therapy against 







2011). The effects of PEST sequence and proteasome inhibitor on dysbindin-1 
protein expression were studied using SH-SY5Y cells stably overexpressing 
either full length dysbindin-1 or its truncated form without its PEST sequence. 
Findings from this study found cells stably overexpressing 1) dysbindin-1 without 
its PEST sequence or 2) full length dysbindin-1A treated with a proteasome 
inhibitor more resistant to oxidative stress as compared to its vehicle control. 
These results put forth the notion that dysbindin-1 protein expression could be 
regulated by its PEST sequence and its protein turnover rate by a proteasome-
dependent manner. However, the possibility of dysbindin-1 proteins degraded by 
a calpain mediated system should not be dismissed as proteins containing PEST 
sequence can also bind Ca2+, and form complexes that are targets for calpain to 
cleave, resulting in its degradation (Shumway et al., 1999; Rasbach et al., 2008). 
Hence, further studies on the role of calpain could also be investigated to shed 
light on another possible pathway modulating dysbindin-1 protein degradation.  
In Chapter 5, possible changes in dysbindin-1 expression after KA 
excitotoxicity was determined. Many studies have shown increased oxidative 
stress after KA induced excitotoxicity (Nakaso et al., 1999; Ong et al., 2000; 
Ibarretxe et al., 2006; Zheng et al., 2011). Hence, KA excitotoxicity could share 
features of H2O2 induced oxidative stress. At 1 day after KA injection, real time 
RT-PCR and Western blot analyses showed no significant change in dysbindin-1 
mRNA expression or protein expression, and immunohistochemical analyses 
which showed an increased dysbindin-1 expression in the DG and CA1, but loss 







in dysbindin-1 expression could be due to increased dysbindin-1 core promoter 
activity, as shown in Chapter 3, or a possible early compensatory response in 
those areas to acute oxidative stress and/or activation of synaptic NMDA 
receptors, which can acutely boost antioxidant defenses (Papadia et al., 2008). 
In contrast, a loss in immunoreactivity in the CA3 ipsilateral to KA injection could 
be due to a higher distribution of AMPA/kainate receptors and sensitivity to Ca2+ 
induced cellular injury in CA3 pyramidal neurons than granule cells in the dentate 
gyrus (McGeer and McGeer, 1982; Wang et al., 2005b). At 2 weeks after KA 
injection, decreased dysbindin-1 immunolabelling was observed in DG, CA3 
while no significant change was observed in CA1. It is possible that high level of 
oxidative stress after KA especially in CA3 (Ong et al., 2000) could result in 
increased proteasomal degradation of dysbindin-1 protein, as found by our in 
vitro studies. Since a majority of the brain dysbindin may exist as a biogenesis 
lysosome-related organelles complex-1 (BLOC-1) (Ghiani et al., 2010), it may 
also be important to determine whether other subunits of the BLOC-1 complex 
are affected by oxidative stress or excitotoxicity in future studies to have a better 
understanding on the etiology and pathogenesis of schizophrenia.  
Taken together, our present results indicate that oxidative stress can 
induce increase in dysbindin-1 transcription through action at its core promoter, 
and also facilitate protein degradation in a proteasome and PEST sequence 
dependent manner. The latter findings are consistent with the view that oxidative 
stress may contribute to dysbindin-1 reductions in schizophrenia. However, 







between the proteasome and PEST sequence of dysbindin-1, which may lead to 
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